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Released for public use in the summer of 2006, Gardasil, America’s first HPV vaccine, 
entered the hearts and minds of the American people without delay. With a growing base of 
awareness to the dangers and prevalence of HPV infection amongst the population, this novel 
prophylactic held the promise of saving lives. Yet, despite the proven efficacy and public health 
benefits, Gardasil became mired in controversy and faced public rejection. Ever since making a 
divisive first impression, HPV vaccines have failed to be effectively utilized. The goal of this 
thesis is to answer the question: Why are HPV vaccines so underutilized in the United States? 
 
The first task is to understand how the vaccine was introduced to the American people 
and what perception this produced. Through an analysis of marketing and political strategies, the 
vaccine’s cultural construction can be determined. The second task is to understand how vaccine 
initiatives have been installed and evaluated following public conceptualization. Finally, through 
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Nowadays, there is a lot of talk about vaccines. Well, one particular, highly anticipated 
vaccine. The ongoing coronavirus pandemic has significantly raised public awareness of matters 
relating to public health and the power of vaccines. While the delivery of a coronavirus vaccine 
promises to save lives and revitalize economies, there will be many obstacles it will face upon its 
release. The vaccine will raise concerns over access to healthcare, the economic interests 
associated with immunizations, and the appropriate role of governmental authority. These 
obstacles will inevitably complicate vaccine delivery and possess the capacity to impede public 
health efforts to save lives.  
 All of these obstacles have been witnessed before. When the Human Papillomavirus 
(HPV) vaccine was released in American markets, the efforts taken by pharmaceutical 
companies, governments, healthcare providers and the public resulted in national division and 
vaccine refusal. By analyzing the pitfalls faced by the HPV vaccine, relevant actors in the 
coronavirus pandemic can identify how to best deliver the new prophylactic and save lives.  
This thesis seeks to answer the question of why the HPV vaccine is so underutilized in 
the United States. I was first drawn to this topic in my sophomore year of college when I had a 
summer internship at MD Anderson Cancer Center. In my time there, I worked with the Head & 
Neck surgery staff and was surprised by the frequency that subjects of HPV and HPV vaccines 
arose. I remember the doctor that I was working with telling me that the majority of the cancer 
patients that he was treating were there because of HPV. He thought it was absurd that despite 
the fact that there was a vaccine that could protect against these cancers, nobody seemed to be 
using it appropriately. He bemoaned the notion that patients would continue to die from a 
preventable disease. If only parents utilized a vaccine with lifesaving potential for their children. 
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As a result of these experiences, I felt compelled to put my energy behind HPV vaccines. 
Immediately following my internship, I was motivated to pursue an initiative on college 
campuses to try and improve vaccine uptake. However, as I did more research on the vaccine, I 
was shocked to discover the fascinating and nuanced history that contributed to the lack of 
utilization. The story was not as straightforward as I had originally understood it. It was not 
simply a matter of there being a lifesaving vaccine that the population failed to use out of 
ignorance. Instead, the vaccine history was entangled in politics, economics, culture, and 
healthcare and was rife with controversy. Never before had I been so enamored by 
pharmaceutical histories. It felt as though I was reading about the scandal of the century and 
human lives were on the line.  
Trying to answer the question of why the HPV vaccine is so underutilized brought me 
through an analysis of the history of immunizations and public health efforts in America. While 
the HPV vaccine was recent in its controversy, many public health initiatives have been poorly 
received due to their reliance on government instituted compulsory policies. Anti-vaxx groups 
are particularly salient in the current political landscape yet vaccines have faced resistance ever 
since they have been ingrained in society. However, the controversies associated with the HPV 
vaccine were particularly fascinating. Gardasil was the first vaccine to appear in a public forum 
following the infamous Lancet article that (falsely) claimed a connection between the MMR 
vaccine and the development of autism (Wakefield et al., 1998). No other debate over 
vaccination had been sensationalized by media outlets and touched on so many avenues of social 
division. As one American policymaker noted when the vaccine first became available, it has 
come to “encapsulate so many issues that are at the core of politics and health policy right now” 
(“Cancer Vaccine Bills Stall”, 2007).  
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When recounting the American story of Gardasil, the first HPV vaccine, nearly all actors 
it encountered contributed to the resistance and division it generated. Pharmaceutical 
powerhouse and Gardasil manufacturer, Merck, as well as politicians, healthcare providers and a 
reactionary public all shared part of the blame for producing a culture of inoculation hesitation. 
In the years surrounding Gardasil’s release, Merck undertook efforts to redefine and restructure 
the public understanding of HPV and their respective vaccine in order to increase the vaccine’s 
profitability. These efforts entangled the HPV vaccine in a political debate that reshaped 
perceptions of immunization through the lens of social and cultural divisions. A divided public 
and healthcare system cultivated a culture of mistrust, resentment and rejection towards a 
prophylactic that possessed the potential to save lives. 
This thesis tackles the question of American HPV vaccine use by detailing these events 
and analyzing their far-reaching effects. The thesis begins by briefly providing relevant 
background information. By exploring topics relating to the American history of vaccine 
reception, the human papillomavirus, and the HPV vaccine itself, the reader can be better 
prepared to navigate the related topics that are further discussed throughout the work. The 
second chapter focuses on the marketing strategies that Merck utilized to enhance the 
profitability of their vaccine. These efforts ultimately contributed to vaccine resistance by 
generating the perception that Gardasil was designed to benefit pharmaceutical wealth rather 
than public health. Chapter three proceeds by outlining the lobbying efforts that Merck pursued 
and the political and public consequences these actions had on vaccine use. By placing the new 
vaccine in a political arena, Gardasil assumed the role of a political tool that produced social and 
cultural divisions that were met with resistance. In chapter four, efforts to improve vaccination 
rates following the vaccine’s political fallout are analyzed. Identifying strengths and weaknesses 
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of these programs allows for a recommendation on how to improve HPV vaccine uptake going 
forward. The thesis concludes with a synthesis of the issues discussed which is facilitated by 
focusing on the contextual relevance of the moment. 
While the failure of a controversial vaccine may not be the scandal of the century, lives 
certainly are on the line. HPV is widespread throughout the population and infection has the 
potential to cause cancer. My hope for this thesis is to raise public awareness of these issues and 
perhaps offer some insight over the pitfalls of vaccine delivery. While vaccines undoubtedly 
possess the potential to save lives, there is no promise that they will be well received and 
appropriately used. As we are all anxiously waiting for a new, and much needed vaccine, it is 
critical to be aware of the difficult road we have travelled thus far so we can better prepare for 




















Background: As a Matter of Fact, These Facts Matter 
The primary focus of this chapter is to go over relevant information and provide the 
reader with a context for the issues that will be discussed. The chapter will begin with a brief 
overview of the history of vaccines in America to yield some insight into the infrastructure that 
the HPV vaccine emerged. It shall proceed by defining HPV as a virus in addition to providing 
some background on disease prevalence and the risks of infection. Finally, the chapter will 
provide a brief exploration of the HPV vaccine with particular attention to its creation, 
effectiveness, utilization, and shortcomings.  
Vaccine Histories: Push and Pushback 
 Since all public health interventions involve inducing a change within a population, they 
act as cultural and social instruments. The history of vaccination efforts in the United States 
highlights the multifaceted implications that come with vaccination and compulsory 
immunization policies. To effectively discuss the cultural effects that HPV vaccines generated 
and their relative lack of utilization, it is important to take into account the social framework that 
they enter into.  
Vaccines have generated controversy throughout their long history. When the British 
military made typhoid vaccination mandatory for its soldiers fighting in Africa during the Boer 
War, it was met with such intense resistance that soldiers protested by throwing shipments of 
vaccines into the sea (Davidson, 2017). This Boston Tea Party-esque moment culminated in the 
military standing down from their mandate and allowing typhoid vaccination to be optional. 
When given the option, 95% of deployed soldiers refused to be vaccinated. This decision 
resulted in the deaths of 9,000 British soldiers as a consequence of typhoid.  
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 Vaccination requirements, like all compulsory health measures, represent an ethical 
dilemma because they involve an intrusion of individual autonomy. Despite this intrusion, 
Government mandates have consistently presented as the most effective form of ensuring 
coverage and improving public health (Colgrove, 2010). Over the history of immunizations in 
the United States, governmental efforts to ensure vaccination occurred over two eras. Both eras 
were defined by sweeping efforts immediately followed by immense pushback.  
The first generation of governmental vaccine interventions arose towards the end of the 
nineteenth century in response to smallpox. Laws that were passed during this period typically 
applied to all members of the general population, adults and children alike. Failure to abide by 
these laws resulted in a variety of penalties for those who refused, including potential fines and 
the threat of imprisonment (Colgrove 2010). As public education began to take hold across the 
nation, the schoolhouse quickly became a hotspot for contagion. To protect youths against 
infection, school age mandates became a popular means of ensuring vaccine uptake. 
Massachusetts, a pioneer in the use of public health law and regulation, became the first to link 
school attendance to proof of immunization in 1855 (Duffy, 1978). 
 Many other states followed suit and in turn the incidence of smallpox was drastically 
reduced (Colgrove 2010). Despite the reduction of disease incidence over the years, the 
population began to rise in resistance to these policies. Perhaps one of the greatest pitfalls to 
immunizations is the consequence of being effective. When populations are protected over long 
periods, a subsequent lack of firsthand experience regarding the terrors of the disease follows. As 
a result, periods of disease reduction were met with a reluctance to comply with vaccine policies. 
With complacency came resistance in the form of court challenges over the use of compulsion. 
Lawsuits over vaccination mandates appeared twice in the U.S. Supreme Court (Jacobson v. 
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Massachusetts, 1905; Zucht v. King, 1922) and in both cases, the court gave affirmations for the 
constitutionality of compulsory vaccination laws.  
 While some considered these shifts towards mandated public health initiatives to be the 
result of a beneficent government, others viewed it as a dangerous trend towards accepting a 
coercive environment. As popular democracy increased through the Progressive Era, so too, did 
anti-vaccination activism (Colgrove 2010). Activists used the new ballot processes that came 
into effect during this era to challenge their states’ laws, resulting in the repeal of mandatory 
school vaccination laws in several states. 
 A second era of government involvement with immunizations was initiated in response to 
a Center for Disease Control (CDC) initiative to eradicate measles in 1968 (Colgrove 2010). To 
support its eradication campaign, the CDC urged states to enact laws requiring school-aged 
mandates for the recently licensed measles vaccine. State compliance with the recommendation 
was rapid and thorough; many of the states introduced mandates for the other recommended 
vaccines. By 1974, forty states had laws that covered all or most of the recommended childhood 
immunizations (CDC, 1978). 
These laws were very much a product of the Great Society era, a period defined by 
activist government (Colgrove 2010). During Lyndon B. Johnson’s administration, 
approximately fifty pieces of legislation related to providing for the health of the population were 
passed. Medicaid and Medicare, enacted in 1965, were the signature products of this period and 
exemplified the notion of a beneficent government that was trying to be established. All of these 
initiatives represented a common impulse: an attempt to remedy health disparities using the tools 
of the administrative state. 
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 Building off the efforts of this era, lawmakers have added more and more mandates for 
new vaccines as they have been licensed. Between 1985 and 2006, the number of vaccines 
recommended by the CDC for children and adolescents doubled from seven to fourteen, and 
states have made most of these newly recommended vaccines school requirements (Colgrove 
2010). School-aged mandates have thus established themselves as the infrastructure that 
vaccination efforts are established through. While there has been little legal pushback in response 
to this rapid expansion, a result due to the presence of exemptions for religious and personal 
beliefs in these new laws, a strong modern-day anti vaccination movement has emerged.  
 While the expansion of vaccination mandates increased resistance to immunizations 
amongst the population, the birth of the modern anti-vaccination movement was a result of the 
1998 paper written by Andrew Wakefield that falsely claimed that MMR vaccination was 
associated with the development of autism (Wakefield et al., 1998). This gave rise to the current 
“anti-vaxxer'' movement that we continue to encounter today. The movement has been bolstered 
by celebrity endorsements as well. In 2007, Jenny McCarthy figure headed the movement after 
her announcing that her son’s autism was caused by the MMR vaccine (Hoffman, 2019). While 
it was determined in 2011 that the claims of the Wakefield paper were based on manipulated data 
and fraudulent research, the damage to the public perception of vaccinations had been done 
(Godlee et al., 2011). As a result of the increase in vaccine hesitancy, the protections that mass 
inoculations confer to a population (herd immunity) have been threatened. The reduction in 
vaccine compliance has resulted in the recurrence of Measles outbreaks throughout the nation, a 
disease that was presumed to be eliminated in 2000 (Measles Explained, n.d.).  
 Throughout their history in the United States, immunizations have caused members of the 
populous to resist the compulsory efforts. Despite these resistances, the use of immunizations has 
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taken hold throughout the nation. The American vaccine infrastructure that has been established 
focuses on the school as the site for instituting vaccination requirements for the population. 
While the incidence of vaccine-preventable-diseases has been greatly reduced in the United 
States through national vaccine uptake, the reduction of disease has reduced the salience of 
disease dangers and increased vaccine reluctance. 
The Human Papillomavirus: A Common Threat 
 While there is an abundance of relevant information to explore when considering HPV, it 
is crucial to provide insight into what the virus really is. HPV stands for Human Papillomavirus. 
Human papillomavirus is defined as any viral DNA that produces papillomas–benign epithelial 
tumors that grow exophytically–amongst humans (NCI Dictionary of Cancer Terms, 2011). In 
other words, HPV is a disease that has the potential to cause warts amongst the infected human 
population.  
Warts, and thus HPV, have a long-known history. The warts that the infection causes 
have been known of since ancient Greek and Roman civilizations (Bäfverstedt, 1967). While the 
physical characteristics of HPV infection are easily noticeable and have allowed for their 
identification, much of the recent understanding of the infection has occurred over the last 
century through the developments of modern medicine and virology.   
As of now, there are over 130 different types of discovered HPVs in the world 
(Davidson, 2017). These virus types, which are named/numbered by their order of discovery, are 
all closely genetically related. Definitionally, each virus type possesses less than a 10% 
difference in their DNA makeup (Aronowitz, 2010). The similarity in viral genetics also 
communicates a similarity amongst these viruses’ means of transmission. All HPV viruses infect 
human skin and mucous membranes and are transmitted through physical contact (HPV Infection 
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- Symptoms and Causes, n.d.). While HPVs possess the potential to cause the manifestation of 
warts in infected individuals, many HPV infections present with little to no symptoms and 
resolve naturally. 
Of the many HPV virus types, about sixty produce warts on the hands, fingers, and face 
(Aronowitz, 2010). This subset of HPV types is relatively common and generally amount to little 
more than cosmetic concerns and discomfort. Amongst this subset are the common plantar warts 
that can be contracted in public showers. While these infections represent the majority of the 
different HPV types, the collective understanding of HPV amongst the public differs. 
Conversationally, HPV generally refers to the 40 types of the virus that are transmitted via sexual 
contact. While the symptoms of potential wart production and the means of transmission through 
physical contact remain the same, the genital location and sexuality associated with the contact 
differ.  
These sexually transmitted HPVs flourish in the soft wet tissues in the genital areas of 
both men and women. Transmission of these HPV types can occur through any form of contact 
with an infected epithelial cell. Due to the ubiquitous nature of sexual transmission, genital HPV 
infections are the most prevalent sexually transmitted infection (STI) in the world (Davidson, 
2017). The CDC estimates that 79 million Americans are infected with HPV currently with 
somewhere between 6-14 million new infections occurring each year, the majority of which 
occur in people aged 15–24 (STD Facts - Human Papillomavirus (HPV), 2019). The lifetime 
incidence of genital HPV infection in the United States is greater than 80% (Fast Facts | HPV, 
n.d.), essentially establishing that infection by some form of genital HPV is synonymous with 
being sexually active. 
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 Efforts to measure the prevalence of HPV in populations have shown that infection 
occurs rapidly after the initiation of sexual activity. A study found that within two years of first 
reported vaginal intercourse, approximately 40% of the female population in the US had some 
form of genital HPV infection (Winer et al., 2008). While the lifetime incidence of the disease 
alone is striking, this finding establishes the immediate presence of risk in sexually active 
populations. The infection is present throughout populations and engaging in any type of sexual 
contact increases the risk of infection. 
Unfortunately, the only true means of protection against contracting an HPV infection are 
through abstinence. While condoms offer a pathway towards reducing the risk of infection, they 
do not assure prevention. Condoms were found to reduce the risk of the HPV infections 
associated with genital warts, however they offered very limited protection against other genital 
HPV infections (Manhart & Koutsky, 2002). Considering the rampant prevalence of the infection 
and the lack of efficacy in safe sex measures, sexually active populations are faced with the 
possibility that contraction of HPVs are an inevitability. 
Amongst laypeople, most HPV awareness is related to genital HPV infections that 
produce genital warts. This is likely because these are the clearest physical manifestations of an 
infection transmitted via sexual contact. Despite greater relative attention paid to these types of 
genital HPVs, only two of the forty HPV types are associated with genital warts (HPV 6 and 11) 
(Davidson, 2017). Infection by these virus types result in the growth of genital warts which tend 
to grow over the course of six months and then stabilize (Fairley & Donovan, 2010). While 
genital warts can be an extremely embarrassing problem, there are no long-term risks associated 
with infection. Infection by these virus types results in no more than cosmetic concerns. While 
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HPV infections cannot be cured, genital warts can be removed surgically–though this procedure 
tends to be expensive and wart recurrence is common (Davidson, 2017). 
Determining the threat that HPVs pose to a population is rather complicated. Considering 
the sheer multitude of HPV virus types, most pose no health risks to the population. Very 
regularly, infected individuals never even become aware of the fact that they have been infected.  
 While most strains of HPV pose no health risk when contracted, a small number–roughly 
15–of the virus types have been linked with cancers and are known to be carcinogenic 
(Davidson, 2017). These strains are known as “high-risk HPVs” and have been linked to 
cervical, vaginal, anal, penile, and oropharyngeal cancers. Out of all of the global cancers that 
are diagnosed on a yearly basis, 5% are caused by HPV infection (de Martel et al., 2012). The 
CDC estimates that about 34,800 HPV-associated cancers are newly diagnosed in the United 
States each year (CDC, 2020). Of these cancers, cervical cancer represents the majority of HPV 
associated cancers worldwide. In fact, 99.7% of cervical cancer cases are a result of HPV 
infection (Clifford et al., 2003). Of the 15 oncogenic high-risk HPV types, two are associated 
with the majority of HPV cancers. These two high risk strains are HPV 16 and HPV 18; they 
account for 70% of cervical cancers and 90% of all other HPV associated cancers (de Martel et 
al., 2012). Global estimates have found that, without preventative intervention, we will see 19 
million cases of cervical cancer and 10 million deaths over the next 65 years (Bruni et al., 2016).  
Cervical cancer used to be the leading cause of cancer death for women in the United 
States until the development of the Pap smear (NIH, 1996). This revolutionary method allowed 
for the detection and excision of precancerous cervical lesions. The death rate from cervical 
cancer has declined dramatically since 1955 (74% from 1955 to 1992) largely from the increased 
use of the Pap smear (McGraw & Ferrante, 2014). This success in reduction, though, has not 
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benefited all populations equally. Pap screenings are generally available only to populations that 
have access to quality health insurance–generally white and socioeconomically secure groups 
(Freeman HP & Wingrove BK, 2005). Pap screenings and the lack of access associated with 
them represents another iteration of the widening divide in health disparities.  
The relative prevalence of cervical cancer versus male-associated HPV cancers has 
resulted in the public perception that HPV is a gendered disease. While the development of 
HPV-associated cancers occurs more rarely in men, infection rates of HPV in males and females 
are equal (McQuillan & Unger, 2017). While female populations are much more susceptible to 
developing HPV-associated cancers, it is important to note a recent trend developing in male 
populations. Occurrence of HPV-associated oropharyngeal cancers have increased by 225% in 
the United States over the past couple decades and have manifested primarily in male 
populations (Chaturvedi et al., 2011). Additional threats to male populations are HPV-associated 
anal cancers, which develop regularly in populations of men who have sex with men (Kim, 
2010). A risk inherent to these cancers is the lack of preventative screenings available to detect 
for their precursors. Precursor lesions have yet to be identified for HPV-associated 
oropharyngeal cancers and, while anal Pap smears exist, they are rarely utilized (CDC, 2012). 
While Pap smears have been an effective tool in reducing female HPV-linked cancer deaths, no 
preventative parallel exists for affected males. 
Though there have been immense advances in oncology, specifically relating to HPVs, 
much remains to be discovered. While it is known that HPV infection itself is a necessary 
condition for the development of some cancers, it is not sufficient (Braun & Phoun, 2010). HPV 
infection is a commonality; cervical cancer is a rarity. Furthermore, the high-risk types of HPV 
may not pose the extent of risk that would be expected with a title of high risk. Despite their 
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dangerous characterization, the vast majority of infections with HPV 16 and HPV 18 are 
transient and generally regress spontaneously without treatment within about two years 
(Schiffman et al., 2007). Despite these uncertainties, the evidence for a causal link between HPV 
and cervical cancer is tighter than almost any other causal association in cancer. 
HPV is an extremely prevalent disease. While there are many virus types, and most are 
not a threat to public health, a small number that are sexually transmitted are linked to the 
development of cancers. HPV-linked cancers are associated with a large number of the world’s 
cancers. Advances in medicine and virology have allowed for many of the characteristics of the 
virus to be identified but the extent of its relationship to the progression of cancer is yet to be 
determined. 
HPV Vaccines: A Light at the End of the Tunnel 
 Taking in the full scope of what HPV is and its associated risks can leave one feeling a 
bit uneasy. Infection seems an absolute certainty and the entire population appears at risk of 
developing cancers. Fortunately, a means of prevention was created: the HPV vaccine. Approved 
for use in 2006, an HPV vaccine entered the market and offered protection against 4 types of 
HPVs–the two highest risk carcinogenic strains (HPV 16 and 18) and the types most associated 
with genital warts (HPV 6 and 11) (Davidson, 2017). Preventing infection by these HPV types 
offered the promise of protection against HPV-associated cancers, especially cervical cancers. 
While pap screening, the only other means of preventing the progression of HPV-related cancers, 
had shown to be quite effective in reducing the rates of cervical cancers, the treatment was no 
more than a secondary means of prevention. The HPV vaccine offered a means of primary 
prevention, eliminating the initiating event and preventing HPV infection as a whole (Brotherton 
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et al., 2016). The vaccine additionally offered a means of protection to male populations, who 
were not able to benefit from HPV associated cancer screening technologies.  
 Today there are three distinct HPV vaccines that have been commercialized: Gardasil and 
Gardasil-9, made by the American pharmaceutical company Merck, and Cervarix, made by 
Britain’s GlaxoSmithKline (Davidson, 2017). Cervarix is a bivalent vaccine that offers 
protection against HPV 16 and 18. Gardasil is a quadrivalent vaccine that offers protection 
against HPV 16, 18, 6, 11. Gardasil-9 represents the update to Merck’s initial vaccine and 
includes protection against 9 HPV types. This nonavalent vaccine protects against the same four 
types that were in the original Gardasil vaccine, in addition to five other carcinogenic associated 
HPV types (HPV 31, 33, 45, 52, and 58).  
 All of these vaccines are administered as intramuscular injections. The vaccines have 
recently been made available to populations aged 9-45 for both male and females. Treatment 
involves the administration of three injections, with the second and third injection taking place 
one month and six months after the initial injection, respectively. In populations under 15, 
though, a two-dose administration has been approved. Younger populations still have developing 
immune systems and with just two injections separated by 6 months, lasting protection can be 
conferred. 
The vaccine itself was a groundbreaking piece of medical technology that utilized 
innovative approaches of conferring immunity to HPV infection in treated populations. 
Researchers that sought to invent an effective vaccine found that by using molecular biology 
tricks, they were able to create something that resembled the virion by using just the protein that 
was most recognizable by antibodies. These artificial virions were called virus-like particles 
(VLP) and were able to generate extremely strong immune responses (Aronowitz, 2010). Most 
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other vaccines have relied on weakening the virus in some way and introducing it to the body 
(Colgrove, 2010). This approach, however, introduces the very risks that are associated with 
natural infection. By using only a single protein to generate VLP, HPV vaccines offered 
protection from infection without posing a risk amongst treated populations.  
 The drug appeared in clinical trials in 1999 and was fast-tracked for FDA approval in 
female populations in 2006 (Davidson, 2017). The trials were faced with a dilemma on both 
ethical and logistical grounds when determining how to measure the vaccine’s efficacy. The 
vaccine aimed to prevent the development of cancers, yet the period from initial infection to 
cancer development was quite long (Lowy & Schiller, 2006). Additionally, the use of cancer–a 
life threatening disease–as a primary endpoint presented as a dangerous situation for patient 
populations. The efficacy data was thus based on whether or not immunized populations 
demonstrated protection against intermediate and high-grade cervical lesions. These lesions were 
defined as necessary precursors to cervical cancer development.  
The data from these clinical efficacy trials showed promising results for these innovative 
vaccines. Both Cervarix and Gardasil gave 100 % protection for the most cancer-proximal 
endpoint while also providing strong protection against genital warts (Lehtinen et al., 2012). 
Additionally, the data showed that vaccination protected against the development of anal and 
vulvar vaginal lesions. However, data on the efficacy of HPV vaccines preventing penile and 
oropharyngeal cancers were limited due to difficulties in identifying premalignant lesions. In 
addition to displaying wonderful efficacy in clinical trials, the HPV vaccine has demonstrated 
stellar effectiveness in public use. A study on its effectiveness showed a 51% reduction in 
HPV16 and/or HPV18 2-3 years post-vaccination and a 73% reduction 4-6 years post-vaccine 
(Mesher et al., 2016). A recent study has demonstrated that by simply receiving one or two shots 
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of the vaccine, as opposed to the complete three-part series, treated populations will receive 
lifelong immunity (Safaeian et al., 2018).  
A common worry amongst populations that resist vaccinations relates to concerns over 
the safety of vaccination. Studies that have tracked the results of HPV vaccinations have found 
that HPV vaccines have an excellent safety record (Macartney et al., 2013). While there are some 
complaints of low-grade and transient injection site reactions, these vaccines have no pattern of 
serious adverse effects. 
While the HPV vaccine presents as a promising piece of biotechnology that stands to 
save millions of lives, there are some concerns that have been raised over its use. HPV vaccines 
protect against a number of HPV types but there is a worry that preventing infection by these 
virus types will only create a vacuum to be filled by other HPV types (Aronowitz, 2010). 
Vaccination aims to reduce the incidence of cervical cancers by a great magnitude but treatment 
could lead patients to discontinue regular Pap smears and miss the progression of other cancers. 
Considering that completing the HPV vaccine has an out of pocket cost of $570, there is a fear 
that the HPV vaccine will only stand to further the socioeconomic divide that produces harmful 
healthcare disparities (Millikan, 2006). 
Despite the potential drawbacks that come with vaccination, the HPV vaccine is 
undeniably a beneficial healthcare product. With their proven track record of safety and 
effectiveness, HPV vaccines have enormous potential for decreasing the burden of HPV-
associated diseases in the world. In the 13 years that the vaccine has been available, it has been 
licensed for use in 82 countries, over 270 million doses have been administered, and an 
estimated 365,000 cases of cervical cancer and 150,000 deaths have been prevented- However, 
because protected individuals are never made aware of what dangers they could have faced, 
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these cases of prevention often go unnoticed and underappreciated. Despite these global 
successes, the vaccine has failed to be effectively utilized in the United States. Due to the 
divisions that were activated and ignited by the roll out of Gardasil, only 53% of girls and 44% 
of boys are up-to-date on their vaccination (Walker, 2017). 
Conclusion 
 Vaccines have a long and storied history in America. While their development has saved 
countless lives, efforts to increase utilization have commonly generated resistance from the 
population. Public health efforts require a little bit of coercion to maximize effectiveness, yet 
compulsory policies ignite debates over the intersection of governmental authority and individual 
liberty. The implementation of vaccine policies has established an infrastructure whereby 
vaccine requirements are incorporated into school attendance for children. The increase in 
vaccines required for children has given rise to a growing anti-vaccination movement that has 
popularized a resistance to immunizations. 
Human Papillomaviruses are extremely common throughout the population. Of the many 
types that exist, a small subset is transmitted sexually and a smaller subset of these sexually 
transmitted viruses are carcinogenic. HPV is the most common STI in the world and is 
responsible for a considerable share of global cancers. Despite the widely held conception that 
HPV is a gendered disease, infection and progression to cancer occurs in both men and women. 
Considerable advances in virology and modern medicine has answered many of the questions 
relating to HPV yet much remains to be discovered. 
The development of the HPV vaccine by Merck and GlaxoSmithKline offered the 
promise of protection and disease prevention. These vaccines have been approved for use in both 
male and female populations and have proven efficacy in clinical trials and effectiveness in the 
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field. While the vaccine has the potential to save lives, there are some concerns that its use may 
impede established preventative practices. Despite this, the vaccine offers an opportunity to 
prevent initial infection of a disease that has demonstrated a clear causal link to cancer. 
By providing an overview of this relevant information, an exploration of the factors that 
have caused the HPV vaccine to be so underutilized in the United States can commence. With 
knowledge over the history of vaccines, the reader has an understanding of the existing vaccine 
infrastructure and the cultural context that surrounded Gardasil when it was released. Detailing 
the prevalence of HPV and the dangers of infection allows the reader to recognize the risky 
environment this virus has produced. Outlining relevant details pertaining to the HPV vaccine 
provides the reader with the opportunity to educate themselves on a vaccine that will be 
discussed extensively throughout this thesis. These details allow one to truly consider why the 












Manufactured Necessity: Marketing Strategies and Profit Motives 
 Merck initiated it’s One Less campaign to promote their new Gardasil vaccine to 
American markets shortly after receiving FDA approval in 2006. The campaign featured a 
widely publicized television ad that featured a diverse, hip, cool group of young girls declaring 
that they would be One Less: One less case of HPV associated cervical cancer. An older woman 
then states, “Gardasil is the only vaccine that may help protect you against the four types of HPV 
that may cause 70% of cervical cancer,” and another (older) woman warns of side effects 
(Merck, 2006). The televised ad was designed to be cutting edge, yet it raised questions and 
concerns among viewers: Where was the urgency coming from? How concerned should one be 
over these potential side effects? Should one really buy fully into a vaccine that only may 
provide protection from four of the many HPV strains? 
This chapter provides an analysis of how Merck approached marketing and selling their 
newly developed HPV vaccine, Gardasil. The marketing campaign undertaken by Merck 
highlighted key notions of how they sought to define the HPV vaccine culturally in America. 
They desired to present Gardasil as a necessary prophylactic for young girls that was 
desexualized to ensure and maximize their products’ profitability. These efforts, though, 
ultimately proved to be barriers towards uptake when the vaccine entered different social and 
political arenas. The sense of necessity that Merck sought to instill amongst the population was 
perceived to be manufactured for economic gain rather than a beneficent effort to increase 
awareness. By tailoring the vaccine for young girls, Merck ignited cultural divisions over gender 
dynamics. The submersion of the sexual components associated with HPV transmission was 
viewed as misleading and limited the public’s trust for Gardasil. Establishing profitability as 
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primary concern, Merck’s high price for their vaccine and risk reduction focus impeded the 
acceptance of the product as a public good. Merck’s efforts to define Gardasil amongst the 
American people proved to activate the various causes for concerns that were then translated into 
vocal criticisms and vaccine resistance. Merck stood to make billions off their vaccine, yet their 
capital focused presentation of Gardasil limited the efficacy of a beneficial healthcare product. 
A Perception of Necessity: I Need It, I Want It 
The manner in which Gardasil presented their novel product to a public eye demonstrated 
how they wanted their vaccine to be perceived. The vaccine espoused a capacity to protect our 
young girls from the imminent danger that threatened them. Merck wanted Gardasil to be seen as 
the chivalrous knight in shining armor that could come to the desperate hand of the nation’s 
distressed damsels. Yet Merck faced large hurdles to overcome if they were to establish a public 
sense of necessity for their innovative immunization. Firstly, the public was poorly educated on 
HPV and there was little common knowledge regarding what the infection was and the 
associated risks it possessed (Blake et al., 2015). Secondly, despite all that was known about 
HPVs and the associated risks of infection, there was not complete knowledge pertaining to the 
causal connection between HPV and the development of HPV associated cancers (Braun & 
Phoun, 2010). Finally, the majority of HPV cancers present as cervical cancer cases and while 
these deaths are common globally, preventative screenings through Pap smears have drastically 
reduced the risk of cervical cancer deaths in the US (McGraw & Ferrante, 2014). Merck faced a 
perilous fate in attempting to establish the need for their vaccine in American markets. They 
somehow had to sell a product to an uneducated market for a problem that already had capable 
treatment while lacking complete understanding of the problem they desired to remedy. While 
the naive public posed a challenge to accomplishing this task, it also allowed for Merck to 
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attempt a molding of public perception towards the most profitable interpretation of HPV and 
Gardasil. By selectively educating the population towards the risks associated with HPV, 
controversial issues relating to sexuality and gender could be submerged, allowing for an ideal 
perception of necessity to take hold. To accomplish this, though, they first had to raise awareness 
to the issue, or in other words, manufacture the public perception of fear.  
Tantamount to Merck’s success in selling Gardasil was increasing public awareness of 
the danger that HPV infection carried. This makes perfect sense upon simple inspection, after all, 
why would a population undergo an invasive procedure without adequate cause? Prior to the 
presence of the vaccine, HPVs were far removed from public knowledge. According to a 2000 
survey, 70 percent of a sample of adults had not heard of HPV and 89 percent had never 
discussed the infection with a health care provider (Kaiser Family Foundation, 2000). Parents of 
girls coming of age in the mid 2000’s, the vaccine’s target demographic, were raised in a 
generation where sexual education classes did very little to educate their students on HPV. In an 
era where the majority of attention was paid to the HIV/AIDS epidemic, sexual education 
programs simply ignored HPVs or approached the infection in such narrow terms that efforts to 
educate on the subject had little learning value (Braun & Phoun, 2010). 
The axiom “if you build it, they will come” does not always ring true. Regardless of how 
revolutionary an HPV vaccine was, if there was no market, the product would fail to be 
effectively utilized. Merck did not want to see Gardasil follow the path of other products where 
developers viewed their product as so innovative that they never stopped to answer the question 
of “who will buy this?”  
Efforts to justify the necessity of emerging vaccine technologies are not novel to 
Gardasil. As it turns out, most newly created vaccines struggle with this due to the simple fact 
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that creating a truly necessary vaccine requires public consensus that they are treating a truly 
threatening disease. A necessary prophylactic is thus directed against a “specific, prevalent, 
serious, and communicable infectious disease” (Aronowitz, 2010, p. 22). Due to the successes of 
previous immunization efforts, potential targets for new vaccines tend to be less prevalent 
conditions that may already have other means of prevention and treatment. Put simply, 
developments of vaccine technologies were products of prioritization. Families in 19th century 
New York City could be expected to be far more concerned about the threat posed by a smallpox 
outbreak than contracting HPV. The diseases for which current vaccines are being developed 
were able to persist for so long in part due to the minimal threat they posed to the greater 
population. While HPV infection does in fact pose a legitimate threat to the population with its 
connection to cancers, the consequences of infection are experienced years later. As the 
consequences of HPV infection are neither soon, certain, nor salient, an HPV vaccine fails to 
generate the perception of necessity amongst the population.  
An effort to remedy the limited understanding of HPV emerged in 2005, prior to FDA 
approval for Merck’s new product. A direct-to-consumer media promotion was launched as a 
non-branded awareness campaign called “Make the Connection” (Siers-Poisson, 2007). This 
campaign focused on raising public awareness about the etiological role of HPV in cervical 
cancer. In American markets, the awareness slogan “Tell Someone” encouraged girls to tell 
someone about the virus that causes cancer. These ads featured female celebrities– Latina actress 
America Ferrera; African-American actress Kimberly Elise; Caucasian actress Elisabeth Rohm– 
who wore bracelets and other campaign-related paraphernalia and discussed the threat that HPV 
posed (Redmond, 2011). Merck spent a reported $107.3 million in advertising, including 
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$841,000 for Internet ads on the human papillomavirus in addition to purchasing 295 TV 
advertisements in the quarter prior Gardasil’s approval (Zimm & Bloom, 2006). 
Merck’s awareness campaign sought to communicate a simple notion: HPV is an 
omnipresent virus that causes cervical cancer. Their unbranded commercials portrayed women as 
fearful and shocked by learning that there was a connection between HPV and cancer.  One such 
ad featured a woman blurting “Scary!” upon learning that a “common virus” causes cancer 
(Merck, 2005). Through these efforts, Merck established themselves as a concerned authority 
seeking to educate the public on a pressing public health issue. Yet, despite this well-to-do 
appearance, not much in terms of health education was actually communicated. The campaign 
did little to nothing to educate the masses on relevant information pertaining to the issue, 
including: not offering any explanation on what HPV is, providing no clarity on how this 
“common virus” is transmitted, and dismissing the notion that HPV can also be transmitted to 
and from men (Redmond, 2011). This awareness campaign communicated a message of fear and 
hopelessness to the people disguised as an effort towards public education. 
The unbranded awareness campaigns that Merck hid behind to establish the need for a 
preventative prophylactic failed to incorporate true awareness into their awareness campaign. 
This lack of communication was not shortsighted, however, but was instead an effort by the 
pharmaceutical company to simplify and more firmly establish the narrative of necessity. 
Acknowledging the limitations in HPV knowledge, the associations with sexuality, and the 
existing yet limited understanding of HPV infection in men would hinder the message Merck 
sought to communicate. Merck was not looking to initiate a conversation over HPV, but was 
rather seeking to establish a sense that the public was living in a state of danger. By submerging 
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relevant details and masking the uncertainties surrounding HPV infection, Merck sought to 
communicate an exaggerated probability of developing cancer in its target markets.  
Core to Merck’s refusal to include health education efforts in their campaigns was an 
anxiety that doing so would make their product less palatable to a consumer public. While a 
causal pathway between cancer and HPV infection had been clearly established, the extent and 
nature of causality in this connection was largely unknown. Little was known as to why some 
HPV infections clear up and remain asymptomatic while others result in the development of 
cancers. Some cofactors–such as smoking, gender, and infection by another type of HPV–have 
been postulated to contribute to the likelihood of disease progression, though no mechanistic 
evidence was available to establish these possibilities (Braun & Phoun, 2010).  
 In addition to lacking a clearly defined and understood relationship between HPV and 
cancer, the “high-risk” HPVs that are delineated as the most dangerous forms of the virus may 
not be as risky as the title may lead one to believe. In fact, the vast majority of infections with 
HPV 16 and HPV 18 are short lived and generally regress spontaneously without treatment 
(Schiffman et al., 2007). This may come as a surprise to most readers, considering the label of 
“high-risk” tends to communicate the idea of a substantial and frightening probability of disease.   
 Acknowledging this lack of certainty and understanding of the causal connection 
between HPV and cancer would act to severely undermine Merck’s efforts towards cultivating a 
public perception of necessity. If the public was made aware to the extent of unknowns 
surrounding the HPV/cancer connection, compliance and uptake could be severely limited. 
Merck thus attempted to erase the complexity associated with the issue by selectively educating 
in a relatively naive population. 
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After gaining FDA approval in 2006 for Gardasil, Merck aggressively marketed their 
product through their “One Less” campaign, sparing no expense. The campaign featured an 
interactive website, television commercials, and branded paraphernalia (Redmond, 2011). As 
discussed previously, these ads featured a diverse array of young women asserting the notion that 
through Gardasil, they could choose to be one less case of cervical cancer. Instead of 
communicating a sense of dread, like Merck’s previous awareness campaigns, the pharma giant 
offered a simple solution to the existing threat that they had primed within the population. 
However, these messages also refused to communicate relevant health information regarding 
HPVs.  
Soon after FDA approval for Gardasil was granted, media outlets began pouring over the 
vaccine, featuring articles that made impressive claims of what the vaccine could do. An article 
in Time magazine stated that Gardasil was an “almost universally hailed … medical triumph … 
the first ever designed to prevent cancer” (Gibbs, 2006). The article goes on to state that cervical 
cancer was “the second most common cancer among women, and the third most deadly in the 
world.” The manner in which this statistic was framed falls in line with the ideology that Merck 
desired to sell, that cervical cancer is the third most lethal to women in the United States, a claim 
that is blatantly false (CDC, 2019). A content analysis of news articles from this period found 
that the type of general information (the transmission, symptoms, and prevalence of HPV) 
articulated in news coverage of the vaccine continued to be limited (Braun & Phoun, 2010). 
While HPV vaccines offer an opportunity to confer immunity to a population from 
dangerous HPVs, it is important to remember that cervical cancer deaths are a relative rarity in 
the United States. Regular Pap smears allow for early detection and excision of precancerous 
lesions and HPV tests are available to determine if an individual should get checkups on a more 
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regular basis to prevent potential progression. All of these facts are absent in Merck’s marketing 
message, a fact that generated significant pushback from the public. Their ad campaigns were 
designed to make cervical cancer appear as an impending and terrifying fate that could only be 
prevented through immunization. Dr. Samantha Gottlieb bemoans this fact in an interview, 
exclaiming “these ads create anxiety and fear when literally nothing in existing gynecological 
practice has changed!” (Garber, 2017). 
The ads were designed to sell products by conjuring powerful emotional responses. Print 
ads that stated “She won’t have to tell him she had HPV … because she doesn’t” capitalize on 
the presence of fear associated with the stigma of STIs and the feelings of worry, shame and 
confusion that are associated with them (Aronowitz, 2010, p. 21). While vaccination offers a 
powerful tool towards reducing the risk of HPV cancers and efforts to improve public awareness 
of their presence are important, marketing messages that obscure relevant information and 
heighten anxiety are more akin to fearmongering than educating. 
Merck’s marketing campaign was subjected to intense scrutiny for the affective approach 
they utilized. Despite the vitriol that arose from their initial campaign, Merck intensified the 
approach of guilting and fearmongering when they released a 2016 ad for their updated vaccine, 
Gardasil-9, which was approved for use in both male and female populations. The new ad 
appeared in two different iterations, one featuring a young man and the other a young woman. 
Both are in their mid-twenties. Gottlieb (2018) describes the ads, 
We see images and videos of the young adults from the past: as images and short video clips fade 
in and out, the narrator ages in reverse, while the older self, the man or woman, narrates his or her 
dismay that when he or she was a child, their parents didn’t choose to vaccinate their child against 
HPV. As the man explains, “I was infected with HPV. Maybe my parents didn’t know how 
widespread HPV is… Maybe they didn’t know I would end up with cancer because of HPV. Maybe 
if they’d known there was a vaccine to help protect me when I was eleven or twelve. Maybe my 
parents just didn’t know.” A young child, presumably the narrator’s past self, asks the camera 
directly, “Right, mom? Right, dad?” The ad ends with a simple orange screen and the words “What 
will you say?” read by an invisible female narrator who encourages parents not to wait, to talk to 
their children’s doctor today. (p. 1) 
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While the threat of developing cancer from HPV infection is genuine, such an ad relies on 
conjuring an intense emotional response to be successful. The ad attempts to elicit strong 
affective responses of guilt, shame, and fear in parents while attempting to invoke a moral 
imperative within parents. “Right mom?”  
 The ad is reminiscent of perhaps the most infamous political ad to be broadcast on 
television: Lyndon B. Johnson’s 1964 presidential “Daisy Girl” ad. The ad opens on a girl 
plucking daisies in a meadow, 
GIRL: One, two, three, four, five, seven, six, six, eight, nine… 
MAN: Ten, nine, eight, seven, six, five, four, three, two, one, zero. 
[Sound of Exploding Bomb] 
LYNDON JOHNSON: These are the stakes: to make a world in which all of God’s children can 
live, are to go into the darkness. We must either love each other or we must die. 
NARRATOR: Vote for President Johnson on November 3rd. The stakes are too high for you to stay 
home (Johnson, 1964). 
 
Yes, perhaps the stakes are high when one considers the threat of HPV infection, just like how 
the stakes were high when voting for a President to determine Cold War foreign policy. Yet 
advertisements that raise the stakes to the nth degree to elicit the most intense of affective 
responses do not produce desirable effects. By instilling a sense of existential despair in their 
audiences, these ads in turn undermine their credibility while alienating viewers.  
By engaging in efforts to overcome the deficits in public knowledge, Merck sought to 
redefine the public understanding of HPV and its connection to cervical cancer. While public 
awareness of HPV increased as a result of the awareness and marketing campaigns, so too did 
concern over Merck’s motivations. The sense of necessity that was core to Merck’s marketing 




A Gendered Drug: Who Runs the World? 
 Gardasil was released under the preface that it was a cervical cancer prevention 
prophylactic. Despite truly existing to prevent HPV infection, a risk present for both genders, 
Gardasil was designed as a women's health drug. While evidence of HPV associated cancers 
occurring in men had been present for 20 years prior to the release of the vaccine, Merck did not 
initially open Gardasil’s market to boys. This notion may be puzzling at first, especially when 
considering that providing the vaccine to both boys and girls would double the size of the target 
market. No, gender dynamics were not at the core of this gendered approach, but rather 
limitations posed by evaluations standards. Despite the demonstrated relationship between HPV 
and the development of cancers in both genders, vaccine efficacy was difficult to prove in male 
populations. HPV cancers that developed in men lacked the easily identifiable precancerous 
lesions that occurred in cases of cervical cancer (CDC, 2012). Providing the vaccine for women 
primarily stemmed from a focus on efficiency, practicality and cost-effectiveness. Navigating 
FDA approval for a cervical cancer vaccine simply seemed to be a far simpler and rapid course 
to get the drug to market.  
Though Merck's gendered approach for Gardasil was not grounded in sexism, it did 
reflect a societal trend in healthcare provision where products are feminized. By focusing on 
women to achieve the elimination of HPV, Merck demonstrated gender biases and 
heteronormative perspectives. Considering that Gardasil was approved for use in boys just three 
years after it was for girls, the impatience that Merck displayed furthers the notion that Merck 
was prioritizing their economic interests over the public health. Restricting HPV vaccine use to 
girls allowed for the vaccine to result in cultural divisions over gender roles and ultimately 
proved injurious towards vaccination efforts. 
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Feminization occurs when an issue's social construction concentrates on females 
(Douglas, 1998). When issues become feminized, the effects tend to result in a characterization 
of the issue as female focused with associated perceptions of power imbalances and 
vulnerability. These notions are particularly captivated by contraception. Displaying the 
associations tied to feminized products, Contraceptives are more costly for women (financially 
and physically), and women thus bear the burden of the procreative responsibility (Davis, 2017). 
Resultantly, contraceptives act to entrench a cultural and social understanding that men are not 
expected to bear responsibility in matters of sexual health (Oudshoorn, 2003). 
 Like contraception, HPV vaccines also aimed to reduce the potential of risky events that 
affect individuals irrespective of gender. Yet, also like contraceptives, HPV vaccines were 
presented as a woman’s issue. Gardasil was a prophylactic for young girls designed to prevent 
the development of cervical cancer. Despite HPV infection and HPV associated cancers 
occurring in both genders, the burden of cost fell squarely on the shoulders of families who had 
young girls. A focus on cervical cancer placed women at the center of all HPV matters and they 
were subsequently expected to bear the burden of HPV reduction responsibilities. 
 Despite contributing to the unfortunate gender biases that exist in healthcare, the HPV 
vaccine initially targeted female populations as a result of the available science at the time. 
Historically, the relationship between HPV and cancer was established through the identification 
of cervical cancers (Epstein, 2010). This long history provided a sounder foundation of 
knowledge for Merck to build from when they sought to release their vaccine. While HPV 
associated cancers had been identified in men, there were no HPV cancers that were as prevalent 
and well understood as cervical cancers. Additionally, with a lack of identifiable endpoints for 
disease progression, any research in male populations would face difficulties in efforts to 
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appropriately measure treatment effects (CDC, 2012). The extent of the threat that HPV infection 
posed in populations irrespective of gender was limited by the scientific understanding at the 
time. As a result, HPV appeared as primarily a women’s issue.  
Public health experts have long understood that the fastest route towards the reduction 
and eradication of HPV infection at a population level would be through a universal vaccination 
program (Colgrove, 2010). If one was to utilize this understanding, boys and girls should both 
have been immunized, even if boys stood to gain little health benefits directly. A non-gender-
based approach stood as a method to reduce the incidence of disease to a point where it did not 
pose a threat to the population. Vaccinating all children promised to spur the development of 
herd immunity in the most efficient manner. While this approach would benefit both boys and 
girls, pharmaceutical manufacturers of the vaccine faced a dilemma: selling parents on the notion 
that their young boys needed a cervical cancer vaccine. Unfortunately, altruism is not that good 
of a selling point. While companies could have attempted to brand the vaccine as a universal 
HPV cancer vaccine, HPV cancers in men were not sufficiently understood, and presented with 
incidence rates that simply seemed too low to justify mass inoculation (Polzer & Knabe, 2012). 
 In addition to opting for the gendered approach as a natural consequence of feasibility 
and circumstance, Gardasil utilized a gendered immunization strategy because of its purported 
cost-effectiveness. Currently, the availability of health care interventions considerably exceeds 
society’s capacity to pay for them (Russell et al., 1996). Believing that herd immunity could be 
conferred to both males and females by ensuring HPV inoculation rates above 75% amongst 
women (Garnock-Jones & Giuliano, 2011), only vaccinating women was a way to reduce the 
costs associated with the provision of care. This line of thinking persisted for a considerable 
period even after Gardasil was approved for boys in 2009, as estimate models portrayed an 
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ungendered approach as medically unnecessary and financially irresponsible (Brisson et al., 
2009).  
By mistakenly framing the question and failing to incorporate relevant data, these models 
produced results that were inadvertently skewed. Approaching the immunization effort through a 
gender biased lens, advocates mistakenly framed the question as, “is it cost-effective to vaccinate 
both males and females compared to females only” rather than asking “is it cost-effective to 
vaccinate both genders compared to not vaccinating anyone at all?” No other immunization 
policy has relied on assessing the cost-effectiveness of a vaccine through gender-based herd 
immunity and such an approach has resulted in a failure to achieve adequate HPV vaccine uptake 
(Daley et al., 2017). Central to the models of cost-effectiveness that relied solely on treating 
women was an assumption of high female vaccine coverage. Unfortunately, the desired rate of 
75% of American women completing the HPV vaccine series has never been achieved. As a 
consequence, both men and women were left vulnerable to the dangers of HPV infection.  
Moreover, a gendered evaluation of herd immunity represented a strategy that was 
particularly vulnerable to penetrations. Attempting to achieve herd immunity by vaccinating half 
of the population allowed for straight men who were not vaccinated to pose a risk to 
unvaccinated female populations. Even if adequate inoculation rates were present amongst 
American females, the global environment is sufficiently dynamic enough that traveling 
American men and women stood to encounter greater risk when appearing in foreign nations 
where HPV vaccination was less common. 
An additional limitation to the gendered herd immunity thesis was demonstrated by the 
approach’s predication on heteronormative worldviews. The initial logic of the HPV vaccine and 
herd immunity was dependent on an assumption that HPV transmission occurred strictly through 
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heterosexual practices. In direct contrast to this, HPV-associated cancers occur at a higher rate in 
men who have sex with men (MSM) than in other straight male populations. In fact, the 
incidence of HPV-linked anal cancer among MSM is higher than the incidence of cervical cancer 
among women (Dietz & Nyberg, 2011). Fortunately, HPV vaccination has proven to reduce the 
incidence of HPV-associated anal carcinomas considerably. However, the lack of vaccine 
recommendation and availability in male populations signaled a disregard and callousness 
towards the lives of a historically oppressed group. By gendering HPV prophylactics, MSM 
populations–a population that was particularly vulnerable to the consequences of HPV infection–
faced a greater hurdle towards accessing much needed care. The assumption of heterosexual 
HPV transmission ignored MSM groups and contributed to the erasure of a particularly 
vulnerable population in healthcare practices. 
The historical association of HPV existing as a gendered disease has contributed to the 
HPV vaccine’s feminization, an association that has consequences for both men and women. 
Due to this gendered understanding, men have been found to be significantly less likely than 
women to know about HPV, the HPV vaccine, and the relationship between the virus and 
cancers (Blake et al., 2015). This paradigm has produced ignorant male populations that are 
particularly vulnerable to the dangers of HPV infection. Additionally, it has contributed to the 
risk experienced by unvaccinated female populations.  
The cultural construction of HPV and its vaccine has contributed to placing an 
unnecessary burden of responsibility on women. Through feminizing HPV and its associated 
prophylactic, long-held beliefs about female responsibility for reproductive healthcare in 
heterosexual partnerships have been reinforced (de Melo-Martín, 2006). Concomitantly, 
feminization delineated the stigma and blame toward women as both the hosts and transmitting 
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agents of HPV (Westbrook & Fourie, 2015). Thus, females are tasked with bearing the burdens 
associated with HPV-related diseases while males fail to accurately gauge their risk of infection. 
As a result, parents of boys consistently underutilize the HPV vaccine demonstrated by the 
disparity in national vaccine completion rates between boys and girls, 44.3% and 53.1%, 
respectively (Walker, 2017).  
Poor vaccination rates amongst men has proven to be consequential towards HPV related 
health outcomes in male populations. Oropharyngeal cancer incidence has increased by 225% in 
the past thirty years and 70 to 90 percent of these cancers are thought to be HPV associated 
(Osazuwa-Peters et al., 2017). Approximately 75% of HPV-associated oropharyngeal cancer 
patients are male and the disease is projected to surpass cervical cancer as the most common 
HPV-linked cancer in the United States by 2020 (Chaturvedi et al., 2011). The dangers of HPV 
infection pose a tangible threat to male populations. The gendered brand that Merck sought to 
attribute to Gardasil has proven to exacerbate these dangers by reducing vaccine delivery to male 
populations. 
The decision to target female populations with a cervical cancer fighting drug was based 
primarily on the existing knowledge of the relationship between HPV and cancer. While this 
method represented a more practical and cost-effective approach for Merck, it was not without 
limitations. By gendering the vaccine, Gardasil became a feminized product that carried with it 
cultural connotations. The gendered dynamic established by an initially female-branded 
prophylactic has cultivated a persistent gender disparity in immunization. 
Sexuality Dynamics: A Not So Sexy Vaccine 
Sex makes things complicated. It has the capacity to make things that may seem simple 
and straightforward out to be more difficult for the parties involved: messier and lost behind the 
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veil of ambiguity. These complicating elements, unfortunately, can also be seen spilling over into 
the realm of healthcare, specifically manifesting with the HPV vaccine.  
Many advertisers have relied on incorporating sexuality to boost their products’ sales. 
However, matters of sexuality that manifest in the provision of healthcare have regularly resulted 
in the stigmatization, politicization, and misrepresentation of beneficial products and practices 
(Polzer & Knabe, 2012). Considering that Merck’s HPV vaccine would be used as a treatment 
amongst adolescent girls, the inherent sexuality tethered to HPV transmission appeared as a 
barrier towards vaccine uptake. Merck identified this fact and considered HPV’s association with 
female sexuality as problematic and capable of reducing Gardasil’s profitability. To assuage this 
possibility, they attempted to present the infection and vaccine in a desexualized context, an 
effort thought to enhance the perception of necessity and reduce the risk of entanglement in 
sexual politics (Braun & Phoun, 2010). However, by completely submerging the sexual nature of 
the virus, Merck appeared as attempting to mislead and manipulate public perception for their 
own economic benefit.  
Many previous healthcare treatments associated with sexual health have faced backlash 
upon their release and integration into practice. Cultural anxieties about female sexuality led to 
critiques of gynecological efforts to introduce routine pelvic exams for adolescent girls. These 
efforts of the 1940’s and 1950’s were considered extremely controversial, particularly amongst 
white and middle-class patient populations (Prescott, 2010). Opponents of the initiative thought 
that exams would threaten the modesty that was so foundational to the adolescent female 
identity. The result was division amongst the public and an enduring struggle to incorporate 
these exams into routine practices. To avoid the potential of a similar fate, Merck presented their 
efforts towards educating an HPV naive public in a desexualized context. 
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In addition to attempting to avoid the pitfalls faced by previous sexualized products, part 
of the desexualization effort was rooted in a desire to further establish the public perception of 
necessity for vaccine uptake. Merck made an effort to present HPV as an infection that people 
simply “got” (Redmond, 2011). In this context, HPV infection would no longer be viewed as a 
contracted STD but merely as a product of existing within an HPV-prevalent environment, thus 
representing the virus as more akin to the common cold than other venereal diseases. These 
endeavors contributed to the cultivation of a risky environment, where HPV was ubiquitous and 
infection was right around the corner. 
Despite the naivety of the public, cervical cancer has long been seen as the natural 
consequence of women engaging in promiscuous behavior. Ever since the disease was observed 
at higher rates amongst married women than nuns, the disease carried with it a moral and social 
judgement over what an acceptable expression of female sexuality looks like (Braun & Phoun, 
2010). However, amongst much of the scientific community there was a concerted effort to deny 
this line of thinking. Instead, scientists attempted to shift the perception of cervical cancer to an 
objective medical issue that carried no inherent judgement of devious behavior. While being 
interviewed, Anna Giuliano, a scientist at the H. Lee Moffit Cancer Center and Research 
Institute, explained that cervical cancer is “not about promiscuity” (Grady, 2007).  In fact, she 
went on to state that “the more we can get that out of people’s minds, the faster we’ll be able to 
get prevention efforts out there.” While this opinion was premised on a motivation to reduce 
persistent sexist biases in medicine, ignoring and obscuring the sexual nature of HPV infection 
was misleading.  
While it may not be the responsibility of a pharmaceutical company to educate the public 
on the connection between HPV and sex, by refusing to do so fortifies predominant 
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misconceptions of sexual health. A strategy of desexualizing Gardasil perpetuates a culture that 
lacks awareness of healthy sexuality and reduces the provision of quality health care (Chesler & 
Kessler, 2010).  This refusal to acknowledge generated movements that sought to reclaim the lost 
female sexuality. An author amongst one of these collectives stated, “The discussion of HPV in 
the mainstream media is largely dominated by information from large pharmaceutical companies 
who currently focus their marketing on cervical cancer; we think this focus on making money 
instead of providing good health care for everyone is fucked up.” (Down There Health 
Collective, 2007). This refusal to acknowledge the role of sexuality has contributed to 
misconceptions amongst the public over the protection that HPV vaccination confers and molded 
women as invisible sexual agents (Braun & Phoun, 2010). Assuaging the inherent sexuality of 
HPV infection additionally reinforces a culture that discourages women from taking ownership 
of their sexual health and perpetuates a stigma of female sexual expression.  
The sexualization of public health interventions has historically posed as a limitation for 
success. Desiring the maximization of product utilization and profits, Merck sought to avoid any 
potential entanglements in sexual politics when bringing Gardasil to market. This refusal 
prevented Merck from defining the relationship between sexuality and their vaccine and allowed 
the public to determine an appropriate reaction. By limiting the information communicated in 
their marketing and awareness campaigns, Merck reinforced misconceptions of sexual health and 
contributed to a naive and reactionary culture. 
Economic Motivations: Cash Rules Everything Around Me 
 Essential to all of Merck’s marketing and branding efforts was a desire to maximize 
profitability for their product. A vaccine that was necessary, desexualized and gendered was 
regarded as the most profitable brand for Merck to ascribe to Gardasil. While vaccines were not 
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always seen as a cash cow in the pharmaceutical industry, developments in biotechnology and 
the pharmaceutical landscape allowed for Gardasil to carry a high price point. Merck’s branding 
of Gardasil as a risk reduction therapy and the vaccine’s high cost limited access to the 
prophylactic. By prioritizing profits over people, Merck came to be viewed as an avaricious actor 
and alienated Gardasil’s customer base. 
Gardasil does indeed present as an extremely beneficial piece of health technology, 
possessing the capability to prevent dangerous infections in at-risk populations. In addition to 
holding the promise of delivering quality care, the vaccine also held the promise of delivering 
quality cash. Through a sole reliance on a direct-to-consumer (DTC) marketing strategy, the 
vaccine was estimated to generate a whopping $4.3 billion in revenue by 2010, just 4 years after 
its release (Silverman, 2005). Ever since the release of the Hepatitis B vaccine, pharmaceutical 
companies disregarded vaccine conceptions of old and instead perceived them as huge money-
making opportunities. However, the economic potential associated with vaccines was still 
relatively novel at the time of Gardasil’s release and the high cost of immunization contributed to 
pushback by the public (Lam, 2015). Gardasil incited questions over how much power should be 
entrusted to big pharma by toeing the line between taking advantage of in-need populations and 
providing a public good. 
While vaccine prices have been rising for years, Gardasil stands out as a particularly 
expensive vaccine. Initially, the vaccine entered the market priced at a high cost of $120 per shot 
or $360 for the complete inoculation series, making it one of the most expensive vaccines in the 
US (Redmond, 2011). Currently, Merck’s updated vaccine, Gardasil-9, has a complete three dose 
out of pocket cost of $570 or more (Fay, 2019). These amounts are considerably higher than the 
costs of other common childhood vaccines (measles, mumps, and rubella, around $35; 
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chickenpox, $58) (Silverman, 2005). While most health insurance providers–both public and 
private–supply the vaccine to clients free of charge, Gardasil’s high cost has generated both 
immense capital and considerable concerns over reduced accessibility. 
Selling at such a high cost communicated Merck’s desire to sell Gardasil to a particular 
market, a market that noticeably did not demonstrate the most need for HPV infection 
prevention. With prices that far exceeded those of contemporary immunizations, the drug would 
not be affordable amongst populations that lacked the means to access quality healthcare. Merck 
was more content with letting Gardasil become the Apple of HPV vaccines; despite reducing the 
market through higher prices, a more expensive vaccine stood to be more profitable than a 
vaccine that was more affordable and accessible. Unfortunately, the market that Merck ignored, 
poor and disadvantaged communities, was excluded from the distribution of a helpful healthcare 
technology despite demonstrating a higher incidence of death from HPV-associated infections 
and a lack of access to other preventive treatments. For those that could not afford to get 
recommended Pap smears as a result of inadequate healthcare, Gardasil and its therapeutic 
effects were luxuries beyond their economic reach. 
Instead of producing a prototypical vaccine, whose primary purpose was to eliminate the 
burden of disease in the population and benefit public health, Gardasil catered more to 
individuals as a risk reduction therapy. Gardasil entered the pharmaceutical market at a period 
when treating risk was the dominant approach. Representative of this paradigm were products 
that prioritized individual focuses and utilized DTC marketing, products like Statins and 
Humulin (Aronowitz, 2010). Risk reducing drugs definitionally promise to “eliminate or control 
the fears, discomfort, and hassles associated with risk” (Aronowitz, 2010, p. 28). Principal to this 
strategy was the fact that it was the experience of risk itself, not just the objective, specific 
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dangers of disease, that such drugs aimed to reduce. Unlike other therapies, the market for risk-
reducing drugs was limitless and the duration of use could be a lifetime. This fact allowed for 
risk-reducing drugs to generate massive capital in the pharmaceutical industry. Merck utilized a 
similar approach in its marketing campaign by branding their product as a means towards 
reducing the experiences of risk associated with HPV infection–particularly the negative and 
emotional experiences of STI stigma. In many ways, Gardasil existed primarily as a risk 
reduction vaccine that prioritized profitability over patient outcomes. 
Not all vaccines possess this economic power. In fact, until recently, vaccine production 
was not a particularly profitable business at all. “Historically vaccines were produced at a 
relatively low price and sold with a low profit margin. They were add-ons to other products—
mostly drugs—that pharmaceutical manufacturers were producing," explains Neal Halsey, 
professor of pediatric infectious diseases and international health at Johns Hopkins Bloomberg 
School of Public Health (Lam, 2015). "The people working in vaccines described themselves as 
the stepchild of others, and they had to fight hard for the resources to develop new vaccines.”  
Vaccines failed to become profitable products during this period due to the wealth of 
competing products. Traditional vaccine development depended on utilizing biological materials, 
usually from tissues from living organisms, when manufacturing immunizations. Once the 
possibility of developing a vaccine had been demonstrated, different biological techniques 
utilizing different biological materials could be used to develop similarly effective products. This 
environment made vaccines technologies from this era particularly difficult to patent (Aronowitz, 
2010). This produced a competitive environment that forced vaccine costs to stay low. Like the 
Hepatitis B vaccine, Gardasil was developed using innovative recombinant DNA technologies 
rather than biologicals. Since these technologies demonstrate high specificity in their production, 
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vaccines produced in this manner have an easy pathway to patent protection. Protecting the 
intellectual property of these vaccines through patents prevented the formation of competition 
and allowed for vaccine prices to remain high.  
These shifts in biotechnology thus reduced market competition and allowed for products 
to dominate within their niche. While DTC risk-reduction-based marketing strategies allowed 
vaccines to generate unprecedented profits, the holy grail for vaccines was to attain a 
government mandate for immunization as a condition of attending school. The vaccine 
infrastructure in the United States was and is built upon state implemented school-aged 
immunization requirements as a condition of attendance (Colgrove, 2010). New vaccines that 
entered the market and demonstrated a sufficient capacity to reduce the incidence of disease were 
incorporated into this infrastructure through state legislation. Obtaining a mandate for a 
particular immunization secured an expansive market for the product in addition to ensuring the 
longevity of its utilization. Subsequently, securing the enactment of school mandates across the 
nation was the ultimate goal for Merck as it was the most definite path towards securing the bag.   
While profits are always a concern for all major corporations, at the time of Gardasil’s 
release it was a particularly pressing concern for Merck. Prior to the vaccine’s release, Merck 
found itself in hot water when it was accused of concealing the risks of its pain medication 
Vioxx; as a result of civil litigation, the firm had been ordered to pay billions of dollars in 
damages (Colgrove, 2010). Fortunately, the projected economic potential of a highly-utilized 
HPV vaccine could rescue Merck from their dire financial straits. When Merck attempted to 
attain a mandate status for their vaccine, some joked that to Merck, HPV stood for “Help Pay for 
Vioxx” (“More Re,” 2007). Merck had a vested interest in recovering from the Vioxx disaster 
and sought to establish Gardasil as their ticket to economic salvation.  
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Merck’s innovative prophylactic was developed in a moment that allowed for the 
immunization to generate unprecedented wealth in vaccine markets in addition to benefiting 
public health. Concomitant to this moment was the growth of skepticism directed towards the 
economic and political power of pharmaceuticals. When Merck attempted to establish mandates 
for Gardasil, these tensions were ignited resulting in a negative public and political evaluation of 
Merck’s profit-over-people approach. Understanding the financial context that Merck existed in 
upon Gardasil’s release contributes to the perception that the vaccine was designed more to 
accomplish capital cultivation than population protection. 
Conclusion 
 Gardasil was the first HPV vaccine product to hit global markets, yet it faced barriers in 
demonstrating its necessity to populations. To effectively sell their product, Merck had to 
overcome: a lack of public knowledge relating to HPV; foundational gaps and limited science 
relating to HPV and its associated cancers; and the presence of a viable and capable substitute for 
their product. While a naive target market posed as a barrier, it also provided Merck with the 
opportunity to attempt manufacturing the ideal public regard towards HPV, its associated issues, 
and the perceived benefits of vaccination by controlling the content and character of their 
awareness and product campaigns. The result was a manipulated and limited message that toed 
the line between raising awareness and fearmongering. While this approach was perceived to be 
the most profitable, it was particularly vulnerable to scrutiny and allowed for a critical perception 
of the vaccine to take hold.  
While the justification for initially focusing development efforts in females was 
predicated on scientific and cost-effective evaluations, such evaluations proved to be faulty and 
misguided. The female focus that Gardasil initially assumed resulted in the feminization of the 
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HPV vaccine and contributed to cultural divisions over gender dynamics. The feminization of the 
product has also contributed to a culture that assuages male responsibility in matters relating to 
their healthcare and places greater blame on females despite greater prevalence of infection in 
male populations. Additionally, the gendered approach has left men, particularly gay men, at a 
greater risk for contraction of the infection and subsequent development of HPV-related cancers. 
Efforts to gender the vaccine helped establish a social understanding of HPV vaccines through a 
gendered lens and contributed to inoculation hesitations. 
 Merck wanted to avoid similar pitfalls of previous healthcare products that addressed 
issues of sexual health when they brought Gardasil to market. Following in the footsteps of other 
scientific thinkers at the time, they presented their prophylactic in a desexualized context hoping 
to skirt potential entanglements in sexual politics. While this effort could be argued as a means to 
erasing sexist regards in healthcare, it also amounts to misleading public perception. When 
Merck faced greater scrutiny after seeking to attain a mandate for their vaccine, attempts to avoid 
entanglement in sexual politics proved futile. As a result, these efforts to desexualize were 
viewed to be manipulative and a product of greater interests in capital generation over the 
provision of care. 
Understanding the financial context that Merck existed in upon Gardasil’s release 
contributes to the perception that the vaccine was designed more to accomplish capital 
cultivation than population protection. Merck’s innovative prophylactic was developed in a 
moment that allowed for the immunization to generate unprecedented wealth in vaccine markets 
in addition to benefiting public health. Concurrent to this moment was the growth of skepticism 
directed towards the economic and political power of pharmaceuticals. These tensions were 
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ignited when Merck attempted to establish mandates for Gardasil, resulting in a negative public 
and political evaluation of Merck’s profit-over-people approach.  
HPV vaccines demonstrate a profound capability to protect populations from an infection 
that has been linked to many of the world’s cancers. Despite the protective potential, Gardasil 
faced barriers towards successful implementation due to a naive public to HPV. Merck 
determined that if the public were to view their product as necessary, desexualized and to benefit 
young girls then they could maximize profitability. Despite their efforts, the marketing 
approaches that Merck utilized activated many cultural tensions. Merck had raised concerns over 
the wealth in the pharmaceutical industry, the ulterior motives of corporations shaping public 
perception, the uncommunicated role of gender and sexuality in HPV and, more broadly, the 
existing divisions over conceptions of gender and sexuality in America. When Merck was caught 
lobbying for school-aged mandates for their vaccine, all of these factors were ignited. Negative 
perceptions from multiple parties resulted in the removal of the vaccine from a healthcare 
domain and into the divisive arena of politics. Alone, any of these efforts may have been 
acceptable, yet when one regards the full system, they help explain the extent of controversy 
associated with the vaccine. The marketing approach taken by Merck directly contributed to the 
sociopolitical controversy associated with the vaccine that has reduced its utilization. While the 









A Political Vaccine: Cultural Consequences of Pharmaceutical Lobbying  
In early February of 2007, while Texas legislators were deliberating a bill that would 
require HPV vaccination for school attendance, Governor Rick Perry made national news by 
preempting their decision:  
Never before have we had an opportunity to prevent cancer with a simple vaccine. 
While I understand the concerns expressed by some, I stand firmly on the side of 
protecting life. The HPV vaccine does not promote sex, it protects women's health. 
In the past, young women who have abstained from sex until marriage have 
contracted HPV from their husbands and faced the difficult task of defeating 
cervical cancer. This vaccine prevents that from happening. 
 
Providing the HPV vaccine doesn't promote sexual promiscuity any more than 
providing the Hepatitis B vaccine promotes drug use. If the medical community 
developed a vaccine for lung cancer, would the same critics oppose it claiming it 
would encourage smoking? 
 
Finally, parents need to know that they have the final decision about whether or not 
their daughter is vaccinated. I am a strong believer in protecting parental rights, 
which is why this executive order allows them to opt out (Perry, 2007). 
 
Perry’s actions fell in direct opposition to the conservative base that had elected him, 
contradicting his standing role as a political, economic, and social conservative. Despite Perry’s 
attempt to align this endorsement with his base, the effort backfired on Perry and Gardasil. 
Within two days, Texas legislators submitted a bill that rejected any HPV vaccine requirements 
in the state (KXAN.com, 2007). Within a month, the state legislature had overturned his order 
and Gardasil had become a symbol of cultural division. 
Vaccines, more than perhaps any other medical technology, distill and highlight the 
relationships of trust and skepticism between the state and its citizens. The HPV vaccine was no 
exception, and wherever the vaccine went, so too did extensive debates regarding the appropriate 
role of governance and the troubling relationship between policy makers, big capital, sexuality, 
and social control. 
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 This chapter details and analyzes the complex interplay that emerged after HPV vaccines 
entered the political sphere. The focus will begin by detailing the cultural moment that Gardasil 
emerged in through an analysis of how Gardasil resembled a different Merck vaccine, 
Recombivax HB for Hepatitis B Virus (HBV). It will follow with an investigation of the 
extensive lobbying campaign Merck utilized to enshrine their vaccine under the legitimacy of 
school age mandates. The chapter will proceed with an analysis of the varieties of skepticism that 
emerged when the policy was debated in a public and political forum. The chapter will conclude 
with an assessment of current HPV utilization and how the implementation of the vaccine shaped 
its acceptance.  
Cultural Context: Recombivax HB, Model Vaccine 
Merck engaged the public in awareness and marketing campaigns for their product by 
utilizing a DTC approach. While this technique was projected to generate billions in profit, 
incorporating Gardasil into the vaccine infrastructure would ensure continued and widespread 
use of the vaccine. Through legislation that mandated girls receive the HPV vaccine as a 
condition of attending school, Merck would establish a perpetual customer base that spanned the 
entire population. Identifying the success of a similar vaccine, Recombivax HB, Merck pursued a 
rapid course for bringing Gardasil before policymakers (Rothman & Rothman, 2009). Despite 
Gardasil and Recombivax’s similarities, there were key differences between the two diseases, 
their respective vaccines, their implementation strategies, and the cultural contexts they emerged 
in. These differences captivated the barriers that Gardasil would encounter when it entered a 




When a new and promising vaccine became available, school mandates were seen as the 
customary choice for policy makers seeking to ensure vaccine use throughout the population. 
Mandates were the established, proven path towards increasing herd immunity and the American 
vaccine infrastructure had been built around it (Colgrove, 2010). When one considers the 
prevalence of HPV in the population and the direct connection that infection has with the 
development of cancers, a mandate seems like a logical option to protect the public health. Such 
a pathway was sure to generate controversy, though, just as previous vaccines did when they 
entered the realm for public debate. At the heart of these controversies are the twin threats of risk 
and coercion. These threats invoke fears about state power vis-à-vis the individual, parental 
rights, violations of children’s bodies, liberty versus the common good, and the intrusive reach of 
science and medicine.  
While controversy was to be assumed by Merck, at face value Gardasil very much 
resembled the HBV vaccine Recombivax HB. Recombivax was also a prophylactic designed by 
Merck and the vaccine had successfully been incorporated into the vaccine infrastructure of 
school mandates with little pushback. There were many similarities between the two vaccines. 
Hepatitis B infection, like HPV, is transmitted sexually and when untreated commonly 
progresses to liver cancer (Hepatitis B Foundation, 2020). The vaccines also both relied on 
similar biotechnologies by utilizing VLPs to confer immunity in treated populations (Aronowitz, 
2010). Ever since Recombivax has been incorporated into vaccine mandate policies, it has been 
considered to be safe, effective, and has widely been utilized (USDHHS & CDC, 2019). 
Identifying the similarities, one may expect Gardasil to follow a similar path; Merck certainly 
did as it based its decision-making process on their HBV vaccine model (Dickerson et al., 2011).  
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Despite Gardasil and Recombivax’s similarities, there were key differences between the 
two which stood as barriers to Gardasil achieving the widespread uptake of Recombivax. While 
Hepatitis B is also connected to sexual transmission, unlike HPV, it is not strictly an STI 
(Hepatitis B Foundation, 2020). This distinction conferred Recombivax with greater resilience to 
the entanglements of sexuality debates. While infection with both viruses can lead to the 
progression of cancers, they differ in the type of cancers that develop. Gardasil focused on 
preventing cervical cancer, a fact that made it much more susceptible to scrutiny over its 
gendered focus, while Recombivax protected against liver cancer, a disease with no gender 
associations. Gardasil was administered in adolescent populations while Recombivax was to be 
administered in young children, a period in life when the specters of puberty and sexuality were 
far less salient (Casper & Carpenter, 2008). Further differentiating the two was their cost. To 
complete the full regimen of immunization, Recombivax cost $69.60 while Gardasil cost 
$390.81 (Dickerson et al., 2011). The increased cost of Gardasil fostered perceptions that the 
vaccine was designed with profit motives that outweighed efforts for public protection. While the 
implementation of a mandate for any vaccine generates concern over governmental authority, 
Gardasil tread upon a number of social issues. The social issues that differentiated Recombivax 
and Gardasil would come to define the controversy of the HPV vaccine.   
The differing rates that the vaccines entered the vaccine infrastructure contributed to 
concerns over Gardasil’s safety and efficacy. Recombivax was slowly incorporated into vaccine 
practices by the government, a fact that allowed it to grow in public acceptance and utilization 
before it was forced on the population. The same cannot be said for Gardasil. From the moment 
that Merck’s HPV vaccine finished clinical trials, the prophylactic was rapidly incorporated into 
the public and political scene. Gardasil had been fast tracked for FDA approval and only five 
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months after being approved for use, legislation had appeared to institute mandates for its use 
(Charo, 2007). Recombivax, on the other hand, was available and used for seven years prior to 
Massachusetts introducing Mandate legislation. Unlike Recombivax HB, the marketing strategy 
for Gardasil was focused more on rapid achievement of sales goals versus a targeted strategy 
toward states with the highest incidence rates of cervical cancer (Dickerson et al., 2011). 
However, without the benefit of a lengthy evaluation period, Gardasil was substantially 
disadvantaged to achieve adoption of school immunization mandates relative to the pace 
established by Recombivax HB. As a result of the rapid introduction to the political forum, 
Gardasil did not have time to become established with consumers as a safe and effective vaccine. 
By prioritizing profit over public health, Merck alienated the American people and damaged the 
reputation of a lifesaving vaccine.  
While Merck may have hoped that Gardasil would follow the path of Recombivax, they 
failed to account for the cultural divide over sexual and health politics that had grown between 
1986 and 2006 when the two vaccines were released. As Casper et Al. (2008) stated, 
“pharmaceuticals do not unfold against the political background when they become available,” 
instead they “interact with and alter the political and cultural landscape – (re)shaping the 
pharmaceutical’s life course in turn” (p. 896). The shifts in public perception over these two 
decades prevented Gardasil from following in Recombivax’s steps. Instead, it created a new path 
that interacted with the cultural and ideological landscapes of the moment. The landscape that 
Gardasil entered was not as receptive to a novel vaccine, particularly one that tread upon the 
cultural divides that were defining the nation. 
In the time between the two vaccines’ release, public acceptance of public health 
measures had seen radical shifts. The period prior to Recombivax’s release saw a rapid growth in 
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public health efforts evidenced by the passing of Medicare and Medicaid. Between 1985 and 
2006, the number of vaccines recommended by the CDC for children and adolescents doubled 
from seven to fourteen (Colgrove, 2010). As a result, the majority of states implemented these 
newly recommended vaccines as school requirements. While there was little legal pushback in 
response to this rapid expansion, a strong anti-vaccination movement had emerged. 
Gardasil entered the political dialogue at a time when the anti-vaccination movement was 
growing in popularity. As the first major vaccine since concerns of a connection between Autism 
and the MMR vaccine were raised, Gardasil was faced with overcoming population wide vaccine 
hesitancy (Hussain et al., 2018.). Recombivax had never encountered such hurdles. Instead, it 
entered a landscape that had been shaped by the AIDS epidemic, a time where the perception of 
disease vulnerability was high amongst the public (CDC, 1986). As Colgrove (2006) argues, 
“because the benefit vaccination offers – the absence of disease – is a ‘negative’ or unapparent 
one, its risks, though rare, seem more salient… the invocation of a certain number of illnesses or 
deaths that did not occur has much less rhetorical force when placed against numbers of vaccine 
adverse events, even if the latter are very few” (p. 8). At the time of Gardasil’s release, diseases 
were not considered a dominant issue and concerns over vaccines had the potential to outweigh 
the benefits. Gardasil and Recombivax were similar in many ways. However, due to differences 
in their respective cultural contexts, Gardasil faced greater difficulties to achieving public 
acceptance.  
Through Recombivax’s success, Merck believed that they possessed a model for 
Gardasil’s installment as a mandated vaccine. While there were many similarities between the 
two vaccines, they were not equatable. Differences in cost, association with gender and 
sexuality, speed of implementation, and cultural contexts all came to limit Gardasil’s reception. 
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Merck, still believing that Recombivax’s incorporation into the vaccine infrastructure was 
sufficient evidence for Gardasil’s success, sought to bring Gardasil before policymakers without 
delay. However, this decision ultimately proved to increase resistance to HPV vaccine mandates 
and damage the lasting reputation of the vaccine.  
Lobbying Efforts: Texas, Our Texas! All Hail the Mighty State! 
While debates over the implementation of an HPV vaccine policy played out all over the 
nation, the most significant scenes occurred in none other than Austin, Texas. At the Women-in-
Government (WIG) Cervical Cancer Summit in 2005, Texas was singled out as a desired proving 
ground for a push to enact liberal HPV vaccination policies into state law (Gottleib, 2018). 
However, this effort seemed to conflict with the prospects of success as the conservative 
legislature had already voiced resistance towards the HPV vaccine (Bustillos, 2016). Despite the 
potential barriers, Merck had well established lobbying connections in Texas that led them to 
believe such an effort was feasible. Seeking to enact a statement vaccination policy in a 
conservative state, Merck aggressively lobbied for the implementation of mandates by 
petitioning Governor Perry and the bipartisan WIG organization for support. While Merck was 
successful in achieving the implementation of a vaccine mandate in Texas, Perry’s executive 
order (RP65) subverted the legislative process and conflicted with the Texan spirit of individual 
autonomy. The policy faced immense resistance and when Merck’s lobbying efforts were 
uncovered, the entire nation erupted in vitriol. Merck succeeded in making Texas Gardasil’s 
proving ground, but the results were disastrous for the pharmaceutical company. The dramatics 
that played out in Texas shaped the national perception that Gardasil was a controversial vaccine 
that was to be met with resistance. 
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Prior to even achieving FDA approval for Gardasil, Merck had been looking for a route 
to bring HPV vaccine policies into effect across the nation. They identified WIG as an 
organization that could champion their efforts. WIG is a group that defines itself as a “non-profit, 
bipartisan organization of women state legislators providing leadership opportunities, 
networking, expert forums, and educational resources to address and resolve public policy 
issues” (Women in Government, 2011). Merck was a corporate sponsor of WIG from 2004 to 
2006 (Siers-Poisson, 2007). In 2004, WIG launched its Challenge to Eliminate Cervical Cancer, 
directly overlapping with Merck’s Make the Connection awareness campaign. Through WIG, 
Merck helped fund the introduction of bills involving the mandated usage, education, or payment 
of HPV vaccine in more than 40 states in between the years of 2006 and 2007 (National 
Conference of State Legislatures, 2018). To accomplish such a task, Merck funded the assembly 
of policy making task forces that were instructed to draft legislation prior to Gardasil even 
receiving FDA approval. At WIG’s behest, Texas was singled out as the proving grounds for 
Gardasil. Thus, the Cervical Cancer Strategic Planning Initiative’s (CCSPI) Policy Work Group 
was formed in Austin. As Dan Bustillos, a former member of the committee, described (2011), 
the group as a conglomeration of “disparate stakeholders, health care professionals, grassroots 
activists, academics, cancer survivors, health economists and health policy wonks” (p. 7) that 
convened to prepare comprehensive policy recommendations on what Texas could and should do 
once Gardasil became available in a few months. 
While the CCSPI was working to draft their policy proposal for Governor Perry, the HPV 
debate had already begun in the Texas legislature. By drafting and submitting legislation for the 
mandatory vaccination against HPV for middle school girls in Texas on November 14th 2006, 
Representative Jessica Farrar (D- Houston) officially began the legislative process in the Texas 
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House of Representatives (The Texas House of Representatives, 2007). Notably, the introduction 
of this bill occurred just five months after Gardasil had been approved by the FDA for use in the 
population. The reaction to the bill was divisive. Political conservatives, religious advocacy 
groups, and parental rights groups criticized the HPV vaccine on moral, religious, and even 
medical grounds while proponents of the bill championed the vaccine’s protective capabilities. 
Critics also claimed that Gardasil was an untested drug rumored to have terrible side effects that 
also promoted promiscuity among young girls. While all of these claims have been discredited, 
they were sufficient to produce a grounded resistance to mandate policies.  
On February 3rd, 2007, the Houston Chronicle front–page headline read: “PERRY 
ORDERS CANCER VIRUS VACCINE FOR YOUNG GIRLS: Texas is 1st state requiring ages 
11 and 12 to guard against sexually passed infection” (Elliott & Ackerman, 2007, p.1). With 
RP65, Perry had stipulated that the Department of Health and Human Services move with all 
speed to implement a vaccination program. It also required the legislature to work on funding for 
the initiative. While the order included a lenient opt-out policy for parents with moral or ethical 
objections, Perry’s decision to issue a mandate through executive order came as a surprise for 
nearly all parties involved. The order seemed to conflict with Perry’s entire brand as a social, 
political, and economic conservative. Adding to the confusion, legislation on the issue was being 
debated on the House floor at the time of the order.  
 The confusion surrounding Perry’s order was so substantial that it prompted a thorough 
investigation to determine the cause of the Governor's unusual behavior. When questioned, 
Governor Perry expressed his personal motivations for such a decision (Charles, 2007). He 
acknowledged that cancer has affected many in his family and that he would do everything he 
could to fight the disease. Perry’s wife, Anita, a nurse and the daughter of a doctor, has been a 
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strong proponent of the order as well.  While these personal reasons for issuing an executive 
order are very noble, they do not tell the full story. Further inspection of Perry’s dealings prior to 
the order revealed a financial connection between Perry, his former chief of staff, WIG and 
Merck. 
On September 10th, 2004, The Austin Chronicle reported that Mike Toomey, Perry’s chief of staff, 
left the state capitol to become a lobbyist for Merck at a time when Merck was making substantial 
donations to both Rick Perry and WIG. In 2005, Toomey functioned as a powerful liaison between 
Merck; his friend and former boss, Rick Perry; and the influential WIG, which counted among their 
Texas contingent Toomey’s former co–worker and his replacement as Perry’s chief–of–staff: 
Dierdre Delisi. Dierdre’s mother–in–law, the Texas state representative Dianne Delisi, was WIG’s 
director in Texas and chaired the Texas House Public Health Committee. Rep. Delisi had also been 
a prominent fixture in WIG’s 2005 Cervical Cancer Summit (delivering a keynote speech alongside 
Anita Perry, Rick Perry’s wife) and had paved the way for the legislative push in Texas. At this 
summit, WIG decided to focus its considerable political force and money to single out a model state 
in which to pass HPV vaccine legislation. WIG leaders, including Rep. Delisi, chose Texas. A Texas 
open records law request showed that Perry had been meeting with Merck lobbyists (including 
Toomey) all through the Fall of 2006. One notable entry, highlighted in Peterson’s February 22nd 
article on Chief of Staff Delisi’s calendar shows that on October 16 she met with other Perry staffers 
for an “HPV Vaccine for Children Briefing”–the same day that Merck made a large donation to 
Perry (Bustillos, 2016, p. 9).  
 
Fueled by revelations connecting Merck’s apparent economic interests with the 
implementation of public policy, public outrage grew and resistance to the vaccine was 
validated. Critics of the executive order complained that any effort to vaccinate the public was 
delegitimized by the economic entanglements between Merck, WIG and Perry. The president of 
the ultraconservative Texas Eagle forum pronounced that this was a case of “‘follow the money’ 
if I’ve ever seen it” (Elliott & Ackerman, 2007).  
The negative perceptions of these economic entanglements were further exacerbated by 
the disclosure that the CCSPI had not even recommended for the implementation of a mandate 
policy. Instead, they recommended a voluntary vaccine program focused on public education and 
budget reallocation that would make the vaccine freely available to the young and poor.  
Recounting the decision, Bustillos (2016) stated that “not only would this policy have a greater 
chance of adoption in Texas than a mandate (and therefore was more likely to lower rates of 
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cervical cancer), it was also more respectful of the Texan ethos and culture” (p.8). Perry had 
issued his executive order just two days after the CCSPI had delivered their policy 
recommendation. Bustillos continued by asserting that the policy recommendation was so 
extensive that Perry and his staff would not have had enough time to read it. A cynical view was 
assumed that Perry had anticipated his order would be dismantled and had hoped to blame the 
action on the policy committee all while lining his coffers. Without a policy committee to blame 
the order on, Perry had to bear the burden of responsibility for his failed executive order, though 
it was Gardasil that paid the true price. 
The negative reactions to the lobbying scandal were so intense that Merck publicly 
aborted its campaign for mandatory vaccination. “We do not want any misperception about 
Merck's role to distract from the ultimate goal of fighting cervical cancer, so Merck has re-
evaluated its approach at the state level and we will not lobby for school requirements for 
Gardasil," explained Mary Elizabeth Blake who served as Senior Director of Public Affairs for 
Merck’s vaccine division (Childs, 2007). As a result of Merck’s lobbying pursuits, Gardasil had 
been stripped of its status as a beneficial pharmaceutical and had assumed the role as a divisive 
political symbol. Public health advocates who were proponents of mandate bills were 
subsequently faced with the burden of justifying Merck’s lobbying actions. Through the cultural 
divisions that the vaccine tread upon and the damaging perception of Merck’s lobbying, a variety 
of criticisms for the vaccine emerged amongst its opponents. Despite the efficacy that Gardasil 
displayed, its reputation and reception was forever mired in the controversy of its political roll 
out. 
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Varieties of Skepticism: Cultural Divisions Embodied 
As the debate over HPV vaccine policies played out across the nation, resistance to the 
efforts were common. Alina Salganicoff, director of women's health policy at the Kaiser Family 
Foundation, it “encapsulates so many issues that are at the core of politics and health policy right 
now” (“Cancer Vaccine Bills Stall,” 2007). While pushback was common amongst the public, 
the reasons for resistance varied greatly. The diversity of responses and varieties of skepticism 
that emerged reveal the questions of governance that exist within the population. In each context 
that the vaccine emerged, it assumed the role of a political tool, opening new possibilities of 
governance and control while provoking the possibility of protest and backlash. All politics are 
local and different sects of the population gravitated towards different reasons for concern when 
Gardasil was presented as a possibility. Amongst the various arguments, common themes 
surrounding vaccine and public health politics emerged: concern over complying with perceived 
coercive efforts by governmental authorities; the special status of adolescent girls as a 
particularly heightened proxy for popular attitudes toward the state; and the routine questioning 
of expert claims when economic motivations may be a guiding force in political decision 
making. The debates that ensued over the public health measures captured divisions that existed 
amongst the population. While many opposed mandate policies, the different arguments that 
were chosen by varying sects of the population proved to further divide the nation. HPV vaccine 
policies from this moment failed to be implemented because they held a mirror to the preexisting 
cultural divisions within the nation. 
As mandate policies were debated, a public divide over the view of government as a 
coercive or beneficent force was displayed. Accusing the City Council of racist paternalism, 
columnist Courtland Milloy (2007) wrote sarcastically that “only the most progressive and caring 
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elected city official– in this case, two nice white people– would propose a program to vaccinate 
against sexually transmitted disease in girls under 13 in a predominantly black school system. 
After all, if the girls’ parents can’t protect them – and, God knows, they can’t protect 
themselves– then somebody’s gotta do it” (p. B1). While the notion that trying to prevent girls 
from developing cervical cancer could be seen as a racist plot may seem far-fetched to some, at 
the core of Milloy’s argument is an existing divide amongst Americans regarding compulsory 
governmental actions. To those who supported a vaccine mandate, it promoted a vision of a 
beneficent government that acted as a super parent– providing resources for families when such 
resources may have initially been unattainable. To those who stood in opposition, though, such 
efforts were seen as the acts of a government overstepping its bounds while impinging on the 
respect of the familial unit. Debates that focused on these distinctions captured the divide that 
persists amongst the population over the desired role that government should fulfill.  
Throughout the country, ambivalence towards governmental authority is deep-seated, 
hearkening back as a founding principle when the nation was first established. American 
attitudes towards Gardasil often reflect a robust suspicion of government, while concurrently 
capturing a strong sense of entitlement within the middle-class towards the resources the 
government provides. Thus, sentiments of “Who are you to tell me to vaccinate my child?” 
communicate a grounded resistance to paternalistic governmental efforts while simultaneously 
establishing a presumption of access to the institutional infrastructure that makes such a 
provision available.  
Despite the infrastructure in place, access to healthcare resources like vaccines and 
preventative screenings are not equal throughout America. Throughout the country, the 
epidemiology of cervical cancer and STDs follows variations in “wealth, resources, medical 
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infrastructure, and social structures– state by state, and across regions within states” (Livingston 
et al., 2010, p. 235). The burden of cervical cancer and HPV infection is concentrated in poor, 
segregated neighborhoods, a pattern that has been proven consistently throughout the nation. A 
WIG report (2008) noted that in Michigan, for example, cervical cancer incidence for whites was 
nearly half what it was for African Americans and Latinas (6.6 per 100,000 versus 11.6 and 11.7, 
respectively). Unfortunately, these disparities were reproduced in mortality rates as well (1.9 per 
100,000 for whites versus 4.2 per 100,000 for African Americans) (p. 43).   
No one likes being told what to do. But by contesting the vaccine policies on grounds of 
resisting governmental authority, a position held by many white conservatives, a level of 
privilege is communicated. While cervical cancer does not pose the threat that it once did in 
many American communities, many continue to suffer from its effects. Access to preventative 
screenings are not a luxury held by all and denying vaccination efforts thus denies an opportunity 
to improve public health and safety throughout the population, particularly amongst those that 
are most affected. 
In accordance with deliberations over HPV mandate policies, similar arguments played 
out while using young women and their sexuality as a proxy battleground. Proponents of a 
vaccine mandate argued that vaccination was the only way to ensure a woman’s safety while 
navigating dangerous sexual terrains. Ruby Bailey, a Michigan obstetrician-gynecologist, argued 
in a March 2007 article that “Your daughter may be a virgin when she goes on her honeymoon, 
but unless her husband was pristine, he may bring [HPV] to the marriage bed… [Without the 
vaccine] One has no ability to protect themselves from the virus” (p.1). While vaccination was a 
sure-fire way to protect the nation’s girls and mandates presented as an effective strategy, many 
remained skeptical of the government’s focus on protecting families and young girls. This 
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dispute played out most directly surrounding the controversial claims that the HPV vaccine 
would encourage adolescent girls to engage in “risk-free” sex. When the questions of vaccines 
were raised, Social conservatives complained “that vaccination could encourage adolescents to 
be more promiscuous” while others alleged that through such a mandate “parents’ authority over 
their daughter’s health care would be usurped” (Levine, 2007, C1).  
The disputes over these disproven claims became so widespread and intense that Gardasil 
no longer operated as a vaccine in the public sphere, but rather as a vehicle for engaging the 
public in debates over positions of female sexuality. While the connection that HPV and Gardasil 
shared with sexuality had initially been skirted by Merck in their marketing campaigns, the issue 
now overshadowed most other aspects about the product. Perhaps such controversy was 
unavoidable with a product like Gardasil, though by taking a backseat role in defining the 
connection and educating the public, Merck was left to watch as the public made their 
prophylactic into a symbol of sexual and political division. 
 Skeptical positions were held by many, but the debates that emerged over the control of 
female sexuality highlighted the sexist ideologies that were present amongst the population. A 
similar story played out in terms of the Hillary Clinton run for president. Consider a hypothetical 
exchange:  
“I don’t think I would vote for Hillary because of her hawkish tendencies and I 
don’t want America to be involved in a global conflict.” 
“Yeah man, you’re totally right, we absolutely cannot have a female president.” 
“Well that’s not really what we were talking about… but I guess it is what we're 
talking about now.” 
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While skepticism over a proposed Gardasil mandate was appropriate, the positions that those in 
opposition assumed displayed the ugly cultural divisions that persisted through the public. While 
all parties that resisted vaccination did not hold sexist viewpoints, these divisive ideologies had 
vocal representation in the debate over Gardasil. The fetishized focus on girls' sexuality that 
played out across the country displayed a cultural divide over the paternalistic zeitgeist of 
controlling women’s bodies.  
Matters of sexuality and paternalism dominated much of the debate over mandate 
policies. However, additional positions of skepticism were held by those with cited concerns 
over the vaccine's efficacy and the financial incentives that mandates represented. The HPV 
vaccine had been publicly available for less than a year when the majority of mandate policies 
were being considered. While Gardasil’s purported safety and efficacy now is supported by years 
of data, at the time, parents had justifiable concerns before adhering to a policy that had potential 
consequences of harming their children. The parents “as guardians of specific children living 
individual lives, wanted proof beyond the quick acceptance of public officials looking to do good 
by a large swath of their constituents” (“Lawmakers Rethinking How to Cure Cancer,” 2007, 
C1).  
 Parents and politicians alike were placed in a difficult role of evaluating whether or not 
they determined the vaccine to be effective. To complicate matters further, at the time that 
political debates over Gardasil were active it was possible to find both unambiguously positive 
and negative claims about the vaccine’s efficacy. Cosette Wheeler, a professor of genetics and 
obstetrics-gynecology in New Mexico, stated in an interview that “the vaccine is 100 percent 
effective against HPV types 16 and 18, which are responsible for the majority of the cancers” 
(Dietz, 2006, F5). Yet it seemed that for every claim that heralded the vaccine, there would be a 
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matching rejoinder. A columnist for the Grand Rapids Press claimed in May 2007 that “new 
data on the controversial HPV vaccine… have raised serious concerns about its efficacy” 
(“Vaccine Faces Scrutiny,” 2007, A3) Lacking consensus over the safety that a decision to 
vaccinate would entail, many parents opted to resist mandate policies to avoid the possibility of 
risk. Despite Merck's effort to brand their vaccine as a risk reducing pharmaceutical, the 
perceptions of risk associated with vaccine use outweighed the perceived risks of HPV. 
As a new economic and public health product, Gardasil generated anxieties in many 
contexts about how the profit motive shaped the push to vaccinate. These anxieties were only 
exacerbated when revelations of Merck’s lobbying and financial dealings with politicians came 
to light. While concerns raised over the products safety and efficacy were quickly dispelled by 
Merck, academic scientists, and public health specialists, the credibility of these dismissals were 
difficult to evaluate due to the economic interests of stakeholders. Subsequently, questions have 
been raised over the appropriate role of the pharmaceutical industry in the development of 
healthcare policy. Upon these revelations, Merck’s advertising campaign slogans, such as 
“cervical cancer kills x women per year” and “your daughter could become one less life affected 
by cervical cancer” (Rothman & Rothman, 2009) appeared to be designed to promote fear rather 
than educate the public to the potential benefits of vaccination. While the presence of economic 
motivations does not necessarily negate the quality of a product, marketing claims must be 
carefully examined against factual data. 
The lobbying practices that Merck engaged in to bring mandate policies to state 
governments was by no means novel. In fact, lobbying practices were customary amongst 
pharmaceutical companies and large corporations (Drutman, 2015). However regular these 
actions were, they were seldomly displayed for the entire nation to react to. The public display of 
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Merck’s lobbying efforts cemented an understanding throughout the population that economic 
motivations were a legitimate factor in HPV vaccine delivery. As a result, the public struggled to 
determine if Gardasil was in fact a commodity for enhancing public health or instead a 
pharmaceutical cash cow. The possibility that both realities could exist concurrently produced a 
cognitive dissonance that left a lasting apprehension over the appropriate role of money in 
politics. 
While there were a variety of reasons that caused the population to resist HPV vaccine 
policies, each and every one was a result of an ongoing cultural debate. By touching on cultural 
divisions relating to the limits of governmental authority, issues of gender/sexuality, and 
corporate influence in politics, Gardasil came to symbolize how parents aligned themselves over 
cultural boundaries. Through Gardasil, the decision to vaccinate your child was a political 
choice. Choosing Gardasil became synonymous with choosing sides in a cultural battle. As a 
result, legislation over mandate policies failed and the HPV vaccine remains divisive in the 
memory of many Americans. 
Prospects Following Pitfalls: Unmet Potential 
 The efforts that Merck engaged in to bring Gardasil to the public impeded effective 
delivery of the vaccine. Merck generated distrust and resistance amongst the population by 
pursuing a marketing campaign that prioritized profits over patients. Utilizing an approach that 
sought to desexualize and gender Gardasil proved to activate cultural divisions and alienate 
Merck’s customer base. The rapid delivery of Gardasil to a political arena further alienated 
consumers as it raised concerns over profit motivations and vaccine safety. Without an 
established foundation of safe utilization throughout the public, compulsory policies heightened 
parental anxieties concerning their children’s safety. When Merck’s lobbying efforts to quickly 
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enact school mandates were discovered, resistance to policies that came to represent a corrupt 
and coercive government was validated. While the public assumed many different positions in 
their vaccine refusal, there was growing consensus that Gardasil was indeed a controversial 
vaccine that merited hostility. 
The effects of the pitfalls that Merck and Gardasil encountered have been enduring. Of 
the 40 states where HPV bills were introduced, only Virginia and the District of Columbia were 
able to pass laws mandating HPV vaccine for females entering the sixth grade, although both 
laws contained a liberal parental opt-out provision (Barraza et al., 2016). In the months and years 
that immediately followed the political efforts to bring Gardasil to America’s girls, HPV 
vaccination rates failed to rise to an acceptable level to confer population protection. A 2010 
survey of HPV vaccine utilization found that only 21% of women reported ever receiving the 
vaccine (Williams, 2013). As a result of this poor uptake, the U.S. Department of Health and 
Human Services (2010) established a goal to bring HPV vaccine rates up to 80% by the end of 
the decade as a part of their HealthyPeople 2020 initiative. Despite this ambitious target without 
mandate policies, the desired results have never been achieved.  
Over the past decade, there have been numerous changes made to HPV vaccine practices 
as an effort to improve utilization rates amongst the population. Merck saw their vaccine 
approved for use in male populations and saw the expansion of age groups such that boys and 
girls between the ages 9-27 qualified for the vaccine. The vaccine is now a routine recommended 
immunization of persons aged 11–12 years and initiation of the series at an early age only 
requires two injections to complete the series (Davidson, 2017). The passing of the Affordable 
Care Act increased access for the vaccine as well, by requiring private health insurers to cover 
HPV and other ACIP-recommended vaccines in addition to prohibiting copays or deductibles 
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when vaccines are delivered by an in-network provider (Schuchat, 2015). The quality of the 
vaccine itself has also seen improvement with the release of Gardasil-9, Merck’s updated vaccine 
that offered protection against five additional HPVs. Through the expansion of the qualifying 
population for treatment, the reduction of cost barriers, and the enhancement of vaccine 
coverage, access to the vaccine has been significantly improved.  
Through these efforts, HPV vaccination rates have seen significant improvement. Yet, 
despite these reductions in barriers, the vaccine has continually underperformed and struggled to 
meet its goals. In the most recent measure of national immunization rates (Walker, 2017), 
coverage with ≥1 dose of HPV vaccine measured at 68.1%, and the percentage of adolescents 
up-to-date with the HPV vaccine series measured at 51.1%. While these rates show improvement 
in vaccine utilization throughout the population, half of the population still remains vulnerable to 
HPV and its cancers. 
A commonly utilized excuse for the lack of HPV vaccine utilization cites the relative 
recency of the vaccine (Dickerson et al., 2011). However, such a narrative no longer remains 
valid as the vaccine has been available for more than a decade. Furthermore, a vaccine that 
emerged after Gardasil has seen greater utilization throughout the population. The Tdap vaccine, 
which became widely utilized after receiving ACIP recommendation in 2011, has an extremely 
high coverage rate of 87.6% (Reagan-Steiner et al., 2015). Therefore, it is critical for the 
understanding of the poor vaccination rates amongst the American population that this is not a 
problem due to recency. Instead, this is a result of the conflicts that played out in the American 
social and political realms.  
The resistance that was demonstrated over Gardasil in the US has not been reproduced in 
other nations. Rather, many other nations have widely adopted HPV vaccines (Dempsey & Patel, 
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2010). As a result of the population adherence to vaccinations, there has been a drastic reduction 
in the incidence of HPV infection and its associated cancers in these nations. In Australia, where 
a national HPV vaccine program had been implemented, recently published data showed that 
78.6% of girls and 72.9% of boys were vaccinated by the age of 15 (Caffrey, 2018). Notably, this 
program was introduced to Australia in the same year of American debates over Gardasil. 
Instead of seeking to immediately introduce a compulsory policy for its citizens, Australia opted 
for a voluntary vaccine program that increased consumer access and allowed for the vaccine to 
become slowly incorporated into their national immunization infrastructure (Walters, 2019). As a 
result of these efforts, Australia now reports the lowest rates of cervical cancer and has seen a 
77% reduction in the incidence of HPV infection (Albeck-Ripka, 2018). This national 
differentiation contributes to the understanding that Merck’s political pitfalls produced an 
environment where HPV vaccine uptake failed to become customary. 
HPV vaccines continue to be poorly utilized in the United States despite efforts to reduce 
barriers. While improvements in access has increased vaccination rates, population goals have 
never been met and half of the nation remains vulnerable to infection. While some may attribute 
the lack of utilization to the vaccine’s recency or an inherent quality to a controversial vaccine, 
these arguments hold little sway. Instead, the lack of immunization uptake is a uniquely 
American, HPV vaccine problem. The political and social consequences of the controversy 
surrounding Gardasil’s introduction serves as a lasting limitation to the vaccine’s efficacy in the 
US. 
Conclusion 
Through Gardasil, Merck had developed a product that promised to drastically reduce the 
prevalence of a harmful and ubiquitous disease while generating billions of dollars in profits. As 
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the current American vaccine infrastructure utilizes school aged mandates as a means to ensure 
immunization uptake, Merck sought to incorporate their vaccine into routine American practices.  
Merck sought to enact legislation across the nation that would impose vaccine requirements for 
Gardasil amongst American, female adolescents. Due to their successful policy efforts with 
Recombivax, which shared many similar attributes to Gardasil, such a task seemed feasible. 
Despite the similarities between the two prophylactics, key differences in terms of price, product 
recency, and cultural contextualization would come to differentiate their public reception and 
political acceptance.  
Using all means at their disposal, Merck carried out intense lobbying campaigns across 
the nation through a reliance on the bipartisan organization WIG. Seeking to achieve a statement 
victory for Gardasil, Merck put the majority of their efforts in Texas to secure the passage of a 
school aged mandate policy. The logic was if Texas could be secured, the rest of the nation 
would follow. Despite Perry issuing an executive order for mandates, the action ultimately failed 
as it subverted the legislative process. When Merck’s lobbying efforts were displayed, it resulted 
in immense pushback to HPV legislation across the nation.  
When Merck’s lobbying campaign became public knowledge, HPV vaccination policies 
and Gardasil itself drew skepticism from a multitude of positions. Through the varieties of 
skepticism, Gardasil was no longer regarded as a simple vaccine. Instead, it adopted a role as a 
politically charged tool that displayed the political and cultural divisions amongst the population. 
Issues over the role of governance, sexuality and economic interests in politics were highlighted. 
Despites Merck’s best efforts, HPV vaccination proved to be a galvanizing force that prevented 
the passage of meaningful legislation.  
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The result of these pitfalls in policy making was the enduring perception that the HPV 
vaccine was controversial. While there have been many efforts to overcome this perception over 
the past decade, the vaccine continues to underperform compared to peer prophylactics. This 
failure to adopt the vaccine has very real consequences for Americans. While cervical cancer 
does not result in as many deaths in America as it once did, HPV-linked cancers continue to kill 
a large number of people. HPV vaccines are a valuable resource that could act to reduce 
population risks, particularly amongst poor, minority, gay and male communities. Despite the 
benefits that such a vaccine proposes to confer to the population, the charged political history 
that is associated with HPV vaccination has proven to drastically impede its utilization. 
While Gardasil’s political history cannot be erased and the passage of any new HPV 
vaccine legislation appears unlikely, there has been considerable effort to improve its uptake 
amongst the public through vaccine initiatives. While most of these efforts have only been 
marginally successful, some have produced significant increases in HPV vaccine uptake. These 
successes demonstrate that the barriers to vaccination can be overcome but may prove to be 
difficult. Many of these initiatives seek to establish in the public mind that Gardasil is just like 
any other vaccine. It is not like any other vaccine, though. The possibility for this conception has 
been stripped from the vaccine as a result of the failures in its presentation. It is unique in its 
political history and its association with cultural complexities. Thus, efforts to improve HPV 




Efforts Against Inertia: Reshaping Immunization Initiatives 
This thesis thus far has sought to answer the question of why the HPV vaccine is 
underutilized in the United States. It has done so by inspecting the product’s marketing, political, 
and social history. The focus now shifts to answering the same question through an analysis of 
how initiatives to improve vaccination rates, performed after the sociopolitical pitfalls of the 
vaccine’s implementation, have been conducted thus far. This analysis was facilitated by 
categorizing the initiatives’ interventional focus as informational, behavioral and environmental. 
Additionally, an analysis of the existing issues in these arenas that contribute to the need for 
change was provided. Among these arenas, successes and failures within programs were 
identified in addition to limitations in their focus and evaluation. The chapter will conclude with 
a synthesis of the material and a recommendation on how HPV vaccine initiatives and their 
evaluations should be conducted going forward.  
Informational Interventions: I Know What I Know 
 Efforts to increase public knowledge were a common focus among many of the initiatives 
to improve HPV vaccination rates. These efforts focused on increasing understanding of the 
HPV virus itself, HPV-related diseases and/or the HPV vaccine. Information campaigns 
conducted thus far have sought to educate treated populations on these issues in an effort to 
increase utilization of the vaccine. Of these campaigns, many resembled the awareness and 
marketing campaigns that Merck engaged in when Gardasil first came to market.  
 Just as when the vaccine first emerged, the public has continued to lack awareness of the 
disease, the threat it poses, and the prophylactic that protects against it. Data collected from a 
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national survey in 2014 found that 32% of Americans had not heard of HPV and its vaccine 
(Blake et al., 2015). The same survey found that 38% of Americans lack knowledge of HPV and 
its role in cervical cancer. Among the surveyed population, females and younger age groups had 
more knowledge of these issues. Contributing to this understanding, a 2019 JAMA Pediatrics 
study (Suk et al., 2019) found that more than 70% of U.S. adults were unaware that human 
papillomavirus (HPV) causes anal, penile, and oral cancers. While public knowledge of HPV 
related information has improved over time, just as its scientific understanding has as well, 
public education on these matters have not been effectively implemented. In most of the United 
States, fewer than half of high schools and only a fifth of middle schools teach all 16 topics 
recommended by the CDC as essential components of sexual health education (NHPC Press 
Release, 2019). Informational initiatives identified the lack of robust knowledge pertaining to 
HPV and its vaccines and sought to improve vaccination rates through educational campaigns. 
Informational interventions that focused on improving public knowledge were successful 
but limited in their scope. Interventions in this capacity were conducted in both individualized 
and community-wide approaches. An individualized intervention in the United States targeted 
low-income parents and provided education on the HPV vaccine (Suryadevara et al., 2013) 
resulting in a 16% increase in vaccine completion when compared to pre-intervention rates 
(p.322). A community-wide media information campaign in the United States targeting 
adolescent boys (Cates et al., 2014) resulted in higher rates of HPV vaccination while the media 
campaign was underway when compared to a control community with no campaign (1.34 hazard 
ratio) (Table 2).  
Informational approaches improved rates of vaccination and were financially feasible. 
Their success was limited, though, by the lack of sustained changes after the intervention was 
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completed. Such initiatives require indefinite maintenance to result in lasting improvements 
which suggests such an approach would not be sufficient when used alone. The reach of these 
programs was also a limitation to their success. While individualized campaigns were more 
effective proportionally, they lacked the scope of community-wide efforts. While vast reach is 
required of initiatives that seek to increase population level vaccine rates, complications emerge 
when one considers the greater level of diversity in a larger target population. Health 
communication programs and materials that succeed in making information relevant to their 
intended audience have proven to be more effective than those that do not (Kreuter & Wray, 
2003). Accounting for the heterogeneity of the population, diversity acts to limit such a 
campaign's efficacy as differing segments of the population have varying levels of response to 
the presented information. Thus, it is difficult to identify any specific educational strategy that 
could be utilized on a broad level. This concept is furthered by the Fu et al. study (2014) that 
reviewed 33 educational interventions and reached the conclusion that no specific strategy 
merited unilateral recommendation. 
Behavioral Interventions: Pushing People to Change 
Informational interventions hoped to produce an increase in vaccine uptake by simply 
providing educational materials to the population, a very hands-off approach. Behavioral 
interventions, on the other hand, were much more involved and dealt directly with the parties 
involved. The majority of identified interventions focused on attempting to produce changes in 
vaccine behaviors by providing necessary skills to make such a decision. These initiatives 
focused on conducting an intervention within either patient or provider populations. Patient 
interventions focused on improving vaccine behavior by either providing decision support or 
reminders. Meanwhile, provider interventions provided training to physicians aimed at 
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improving clinical behaviors when providing a vaccine recommendation. As cooperation was 
needed by both parties to ensure the administration of vaccines, an optimization of the behaviors 
on both ends promised to improve vaccine use. 
When considering the need for an intervention at the patient level, one must weigh the 
role of the parent in the decision-making process. While the adolescent is the patient in the case 
of HPV vaccination, only parents can provide consent to initiate immunization practices (English 
et al., 2008). Unfortunately, parental refusal is a common occurrence when it comes to the HPV 
vaccine. According to Anna Beavis, MD, MPH, a gynecologic oncologist fellow at Johns 
Hopkins University, one in 5 parents of adolescent sons and 1 in 10 parents of adolescent 
daughters refuse the vaccine (Caffrey, 2018). Common reasons for refusal include concern over 
vaccine safety, a perceived lack of necessity and a lack of knowledge (Beavis et al., 2018). 
Notably, concerns relating to promiscuity and sexuality were not listed amongst these reasons. 
This fact provides pushback to the notion that sexuality is considered to be the primary issue 
when it comes to a parent’s refusal of the HPV vaccine.  
Behavioral interventions that were conducted amongst patient populations showed some 
success, though they did not achieve desired results. Message framing studies (Gerend & 
Shepherd, 2012; Hopfer, 2012; Rickert et al., 2015) sought to determine if the manner that HPV 
and vaccine information was presented to patients impacted their choice to vaccinate. Studies 
that utilized this approach were largely unsuccessful. However, Hopfer’s (2012) study identified 
that amongst college-aged populations, peer recommendations carried greater weight than expert 
recommendations. These studies mostly demonstrated an increase in intent amongst treated 
groups rather than an increase in vaccine behavior. Unlike message-framing interventions, 
studies that provided patients and their parents with reminders to vaccinate (Chao et al., 2015; 
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Kharbanda et al., 2011) proved to be successful in achieving behavior changes. By providing 
mail and text message reminders to schedule a routine immunization appointment, HPV vaccine 
utilization was significantly increased. The magnitude of this increase in vaccine behavior, 
though, was not on the order of the desired Healthy People 2020 goals.  
 The role of the physician in providing a recommendation for HPV vaccination is critical 
to increasing uptake. In fact, the single biggest barrier to increasing HPV vaccination is not 
receiving a health care provider's recommendation (Gilkey et al., 2016). Unfortunately, a large 
number of physicians do not provide a quality recommendation. Amongst the population of 
parents that did not vaccinate their children against HPV, 10 % of parents of girls and 17% of 
parents of boys identified the lack of a provider recommendation as the primary reason to not 
vaccinate (Beavis et al., 2018). Taking these statistics into account, it appears that physicians 
have failed to effectively perform their duties to ensure quality vaccination rates. The CDC 
outlines specific guidelines on how to perform a vaccine recommendation that utilizes a 
“presumptive approach” (Talking with Parents about Vaccines for Infants | CDC, 2019). In this 
method, the doctor makes an announcement that assumes parents are ready to vaccinate their 
children, versus a conversational style that engages parents in an open-ended discussion. A study 
conducted by Opel et al. (2015) determined that this approach maximized parental compliance in 
vaccine recommendation. By contrast, 16% of pediatricians and 24% of family physicians said 
they instead use a conversational style when bringing up the issue (Kempe et al., 2019; Figure 1). 
While rectifying this deficiency is imperative to improving the rates of HPV immunization, such 
an accomplishment requires an identification of the many difficulties that providers face while 
recommending vaccination.  
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Many doctors have vocalized anxiety over HPV vaccine recommendation (Allison et al., 
2016). Due to the loaded history of the vaccine, many parents refuse the vaccine when it is 
offered. This anticipation of refusal has left some doctors concerned that recommending the 
vaccine would cause patients to seek care elsewhere (Gilkey et al., 2016). The anticipation of 
parental refusal may also cause providers to adjust their recommendation style. This scenario 
results in a self-perpetuating cycle. Kempe et al. (2019) described it as such, “the circular nature 
of provider anticipation of refusal or deferral potentially lead[s] to a weaker recommendation 
style and less persistence in responding to parental hesitancy" (p.7). The loaded history of HPV 
vaccines and the anticipation of parental refusal cause providers to treat the HPV vaccine 
differently than other vaccines. Parents that identify this difference subsequently view the HPV 
vaccine as an immunization that requires more thought—an immunization that is not to be 
expected. While the HPV vaccine is by no means just another vaccine, like other vaccines it 
possesses the potential to protect children from a life-threatening disease. The political pitfalls 
that Gardasil faced have conferred a lasting impression on healthcare providers that inhibit their 
capacity to save lives. 
Studies that performed behavioral interventions at the provider level (Gilkey et al., 2014; 
Perkins et al., 2015) provided physicians with training on how to best navigate parental pushback 
and improve the quality of their recommendation. These interventions used a version of the 
Centers for Disease Control and Prevention–endorsed Assessment/Feedback/Incentive/Exchange 
(AFIX) approach. Perkins et al. (2015) compared HPV vaccination rates at clinics randomized to 
the AFIX approach versus control clinics and demonstrated a significant increase in HPV uptake, 
most impressively among boys. Gilkey et al. (2014) sought to determine the best means of 
delivery for applying AFIX training for physicians. By testing and comparing the results of an 
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in-person AFIX consultation, a webinar AFIX consultation, and a control group, it was 
determined that in person training resulted in the greatest improvement in vaccine uptake 
behavior, though webinars were effective as well. Both studies commented on the high level of 
acceptability of the intervention by key stakeholders. 
Behavioral interventions at both the provider level and the patient level resulted in an 
increase in vaccine uptake, though these results were magnified when they were conducted 
concurrently. Two studies (Cassidy et al., 2014; Fiks et al., 2013) were identified that utilized 
such an approach and the findings indicated that a combined approach resulted in the highest 
rates of vaccination initiation and completion. By using a combined approach that utilized 
family-focused reminders coupled with clinician-focused reminders and education, the studies 
resulted in a significant increase in vaccine initiation compared to the control group. The authors 
of these studies also commented that the implementation of these programs was simple and that 
parents welcomed the information provided.  
Behavioral interventions represent a tangible means of increasing vaccine behavior. 
Interventions that focused on the patient were low in cost though alone failed to generate much 
more than an increase in intent to vaccinate. This approach has considerable limitations 
considering that the effective delivery of patient reminders requires a maintenance of up to date 
patient information. Additionally, such an approach would require a sustained application of 
practices as patient populations graduate upon completing the vaccine series.  
Interventions that were applied at the provider level, however, resulted in lasting changes 
after the intervention was applied. These interventions resulted in a significant increase in 
vaccine behavior, though they are limited by the scope that they can be applied at. Barriers to 
wide implementation of in-person interventions include time requirements for already busy 
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physicians in addition to requiring physician compliance and engagement. While in-person 
training resulted in the greatest increase in vaccine behaviors, webinars have the benefit of 
increasing the reach of providers who could participate. The American Academy of Pediatrics 
recently developed an app for physicians that seeks to overcome the limitations of in-person 
training (Korioth, 2018). The “HPV Vaccine: Same Way, Same Day” app is a module-based 
program that is engaging and allows physicians to complete the material on their own time. This 
app provides an interactive training program for physicians so they can hone their vaccine-
recommendation skills. The app also provides insight on how physicians can communicate with 
a parent that vocalizes concern for the vaccine even when the proper recommendation technique 
has been utilized. By training doctors in skills like motivational interviewing, they can be best 
prepared to handle parental concern appropriately and increase vaccine uptake. The app is 
delivered in short modules and can be completed in a little more than 40 minutes. By 
synthesizing the beneficial aspects of in-person and webinar interventions, the app seeks to 
maximize provider training and increase vaccine behavior. 
Both patient and provider based behavioral interventions increased HPV vaccine use. 
However, the greatest effects were observed when these approaches were used in conjunction 
with one another. While provider targeted interventions were more successful for vaccine series 
initiation, it was patient targeted interventions that were most successful for series completion. 
These results indicate that providers pose the greatest barrier to vaccine series initiation, while 
patient or family barriers are a greater hindrance to series completion. These findings indicate 
that behavioral interventions represent a tangible means of increasing vaccine behavior. 
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Environmental Interventions: Addressing the Landscape 
 Of the initiatives studied, those that had the greatest reach were the ones that 
implemented interventions at the environmental level. These efforts sought to enact change by 
altering the social environment in order to facilitate vaccination. By introducing new vaccine 
opportunities for targeted communities, a greater proportion of the population was able to 
participate in vaccination. While the most effective efforts at this level involved participation of 
local and national governments, such initiatives did not meet the same level of success in the 
United States as they did in other countries. Most efforts in the US incorporated the use of 
school-based vaccine programs.  
The need for governmental involvement in vaccine programs to achieve population level 
protection is well established (Colgrove, 2010). In the US, the existing vaccine infrastructure 
only has the means of implementing requirements at a state level through school attendance 
requirements. Due to the complicated sociopolitical history of the HPV vaccine, governmental 
implementation of such policies has proven largely unsuccessful. A recent exception to this, 
though, is the state of Rhode Island. In 2015, the Rhode Island Department of Health decided to 
require the vaccine for all seventh graders (National Conference of State Legislatures, 2018). To 
accomplish this task, the Department utilized their authority over public health matters to 
implement the requirement without legislative approval. As a result of this action, the most 
recent CDC National Immunization Survey for Teens (NIS-teen) (Hill, 2018) demonstrated that 
Rhode Island had the highest vaccination coverage rates for the completion of HPV vaccine 
series (2 or 3 doses) for both male and female adolescents 13-17 years of age (78.1%) in the 
nation. The survey showed that other jurisdictions with school entry requirements had high HPV 
vaccine coverage as well (DC 78%, Virginia 59%). The argument for the effectiveness of 
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governmental involvement is furthered when one considers Australia. Australia was the first 
country to institute a national HPV program and observed high completion rates at both 1 and 5 
years after the program was implemented (77% and 70%, respectively) (Brotherton et al., 2008; 
2013). Considering these data, governmental involvement proves to be the most effective means 
of increasing vaccine rates. However, successful implementation requires active participation 
and approval of policymakers and the public.  
Since the majority of states in the US have not enacted vaccine requirements for the HPV 
vaccine, environmental interventions sought to implement their initiatives as close to the existing 
vaccine infrastructure as possible. This effort to operate within social expectations resulted in the 
utilization of school-based vaccine programs. Five studies that utilized a school-based program 
in participating American middle schools were identified: 4 offered the vaccine for free (Caskey 
et al., 2013; Gold et al., 2011; Kempe et al., 2012; Stubbs et al., 2014) and one billed to 
insurance (Daley et al., 2014). Of the free programs, the study conducted by Kempe et al. (2012) 
proved to be most effective and demonstrated an initiation rate similar to national averages 
(59%), a dramatic improvement over the pre-intervention rate of 5% (Table 2). However, none 
of the participants completed the vaccine series. The remaining programs did not find the same 
success as the first, however, as they all reported rates well below national averages. The Stubbs 
et al. study (2014) only resulted in initiation and completion rates of 6% and 4.8%, respectively 
(Table 2). These programs struggled primarily due to the lack of participation amongst the 
student population. The difficulties posed by acquiring parental consent resulted in an average 
participation rate of 2% through these remaining studies.   
Two studies (Moore et al., 2010; Navarrete et al., 2014) sought to circumvent the 
challenges posed by acquiring parental consent by targeting university students in their 
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interventions. Both programs offered the vaccine free of charge and proved to increase both 
initiation and completion rates. The Navarrete et al. study (2014) was supported by the Merck 
patient assistance program and targeted underinsured students. The intervention was coupled 
with patient reminders and resulted in an 89% initiation and 48.3% completion rate (Table 1). 
When environmental initiatives were implemented, they consistently reached the greatest 
number of participants. The most successful of these interventions achieved the highest 
vaccination rates out of all of the initiatives studied. However, the results of these approaches 
were not consistent. At their core these approaches were effective, at points more so than 
initiatives involving an informational or behavioral approach. Environmental interventions had 
the greatest overall cost, though they continued to be cost-effective and well-received amongst 
participants. While many of the school-based programs did not achieve desired initiation rates, 
the majority of participants that initiated the vaccine series completed it as well. 
These programs were not without limitations, however. In school-based programs, 
researchers consistently faced significant barriers, including stipulations to vaccine 
administration and low participation rates. School-based programs have proven to be more 
consistently successful in international settings than domestically (Walling et al., 2016). The 
relative difference is likely a consequence of the vaccine infrastructure in the United States, 
where immunizations are connected with pediatric visits as opposed to school-based clinics. 
Without being established as a social norm, school-based programs struggled to overcome the 
perception of novelty and generate population participation. While the greater reach of 
environmental approaches is a strength of these programs, it also makes successful 
implementation more difficult. Successful school-based programs require active participation by 
teachers, students, and parents. By involving a greater number of actors, there is a greater chance 
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of encountering resistance amongst the target population. Without adequate community support, 
these programs fail to generate sufficient participation and become ineffective in achieving 
significant improvements in vaccination rates. 
Initiatives to date have proven to be moderately successful though such successes rarely 
met national averages or goals. While there is a definite advantage to interventions that have a 
wide scope and seek to produce a change in vaccine behavior amongst the largest population, 
this advantage also acts as a limitation due to the heterogeneity of the population. One consistent 
deficiency in nearly all of the studies analyzed was the lack of data on race/ethnicity and 
socioeconomic status. This lack of data made it difficult to determine whether or not certain 
interventions proved to be more effective amongst different segments of the population. Given 
the significant disparity in outcomes of HPV related diseases, it is imperative to develop a better 
understanding of the relationship between demographics and vaccination behavior.   
Without any knowledge of the characteristics of the treated audience, the reproducibility 
of successful interventions is limited. The effects of these initiatives are understood through a 
macro lens, where the target population is the general American populace and changes in 
immunization rates are measured at the national or state level (Rahman et al., 2014). The 
American people are not a generalizable group, however. The diversity of the nation and 
heterogeneity of its people would limit the efficacy of any nationwide initiative since different 
populations respond better to different methods. In fact, Lee & Garland have suggested that 
public health proposals to increase the uptake of the HPV vaccine within a population are most 
effective when tailored to a specific population (2017). By refocusing how initiatives are 
conducted and evaluated to be more attuned with the community they are implemented in, HPV 
vaccine utilization can be improved. Identifying the sociodemographic characteristics of 
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communities where interventions have been successful provides a pathway towards 
reproducibility and broader implementation. 
Regional Focuses: Macro to Micro 
Demographics related to HPV vaccination uptake can vary widely, even between 
adjacent counties within the same state (Hill, 2018). Most studies to date rely on data from the 
NIS-teen to determine the population efficacy of initiatives (Walker, 2017). Recently, enough 
data was collected in this survey to measure immunization rates in different counties within the 
state of Texas. By analyzing the variation in HPV vaccination rates within a state, a deeper 
understanding of the causality that demographic and community factors have on vaccine uptake 
can be cultivated.  
A study by Conrey et al. (2020) compared data from Dallas County, El Paso County, 
Travis County, Bexar County, the City of Houston, and the rest of the state and found significant 
differences in rates of both initiation and completion of the HPV vaccination series. In fact, 
residence in Dallas County was a significant predictor of failing to initiate the HPV vaccine 
series. When adjusting for sociodemographic characteristics, which also varied significantly 
between the regions, residence in Dallas County continued to be a predictor in a lack of vaccine 
initiation. This indicates that a cultural factor that cannot be explained by sociodemographic data 
exists in Dallas County that contributes to vaccine behavior. El Paso County, on the other hand, 
demonstrated the highest rates of vaccine initiation and completion between the six regions. 
While the state of Texas had one of the lowest rates of HPV vaccination uptake in the nation, El 
Paso County had the fifth highest initiation rate and fourth highest completion rate of all the 
areas surveyed by the NIS-Teen in 2016 (Walker, 2017). 
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The relatively greater rates of vaccination in El Paso can potentially be explained by 
considering the characteristics associated with sociodemographic factors of the counties 
populous. As the region is situated on the US-Mexico border, a large number of the county's 
residents are Hispanic when compared to other regions in the state. Hispanic women in the US-
Mexico border region are significantly more likely to be diagnosed with cervical cancer than 
non-Hispanic women (Coughlin et al., 2008). Considering these findings in conjunction with 
studies that have demonstrated a positive correlation between HPV vaccine uptake and perceived 
risk of HPV-related cancers provides a rationale for the greater rates of vaccine behavior in El 
Paso County. Additionally, El Paso County successfully implemented a culturally-tailored HPV 
vaccine campaign that improved vaccination rates across the county (Molokwu et al., 2019). 
The success of the culturally-tailored HPV vaccine campaign in El Paso serves as a guide 
to optimize public health efforts that seek to improve vaccine utilization. This program utilized a 
multicomponent (education, navigation and access provision) culturally tailored and evidence-
based HPV approach to measure the effects on actual vaccine completion rates in a 
predominantly low-income Hispanic community. In this study, efforts were taken to develop an 
understanding of the community before the implementation of the intervention. Focus groups 
were deployed to identify cultural concerns, barriers and knowledge gaps specific to the 
community. By engaging the population and identifying community specific needs, educational, 
navigational and provisional efforts were adapted to best fit the population the program was 
targeting. The intervention significantly improved HPV immunization rates in the community 
and represents an advancement in the administration of public health initiatives. 
These data on regional vaccine use demonstrate that variation in HPV vaccination uptake 
occurs within differing regions of the same state. It is likely that if enough data were collected on 
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vaccination rates for all states to provide county specific data, similar findings would be 
demonstrated. The relationships portrayed through these data illustrate the importance of 
examining smaller, more homogeneous regions when developing public health interventions 
aimed at increasing vaccination uptake. By developing a cultural understanding of local regions 
and implementing interventions through that understanding, a greater proportion of the 
population may be protected from the development of life-threatening diseases. 
Synthesis & Suggestions 
 Numerous approaches have sought to improve HPV vaccination rates. By categorizing 
these efforts by their approach, patterns of success and failure can be identified. By examining 
and synthesizing the myriad interventions that sought to improve HPV vaccination uptake rates, 
an ideal intervention can be constructed.  
Environmental approaches have demonstrated the greatest successes of the programs 
studied in this thesis. Environmental interventions are most successful when they are applied 
through governmental channels, but these channels have been stymied in the US. As the vaccine 
infrastructure in the United States is built upon individual states enacting school-aged mandates, 
the HPV vaccine’s complicated political history has generally prevented the enactment of state 
mandates. Rhode Island’s recent HPV policy goes against this, though, and may demonstrate 
changes in HPV vaccine’s political narrative and increased public acceptance. Considering the 
extremely high rates of HPV vaccine completion in Rhode Island (78%), incorporation of state 
policies for mandates presents as the best avenue for achieving vaccination goals of 80%. 
The average age of a new mother in the US is 26 (Bui & Miller, 2018). By this fact, these 
mothers were 13 years old when the political drama of Gardasil played out across the nation. As 
memories associated with the divisive roll out of HPV vaccine policies of the late 2000’s fade, 
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the loaded history of HPV vaccination has less sway as a preventative measure on the enactment 
of HPV legislation. Thus, the fading memory of the cultural associations with HPV vaccines 
represents an opportunity to reshape the public perception of the prophylactic. This opportunity 
should be capitalized upon to prevent the vaccine from acting as a symbol of cultural division, 
and instead assume the role of another routine immunization. By accomplishing this task, the 
barriers to vaccine legislation can be dismantled and policies can successfully be enacted. 
Until such a task is accomplished, though, environmental interventions must utilize 
school-based vaccine programs. While these programs have demonstrated success, the cultural 
novelty of such programs in the US and the requisite for broad community support limit these 
programs' efficacy. To bolster the successes of these programs, they should be conducted 
through local infrastructures to incorporate effective cultural knowledge of the targeted region.   
While the memory of Gardasil’s rollout may be beginning to fade amongst the American 
people, as of now many parents continue to refuse HPV vaccination for their children. When 
such events occur, the best strategic approach utilizes patient- and provider-focused behavioral 
interventions. Data has consistently demonstrated that provider recommendations are the 
strongest predictor of initiation of the HPV vaccine series. Many providers fail to effectively 
implement a strong recommendation for their patients by utilizing a presumptive approach and 
instead opt to initially engage in a dialogue with parents about the HPV vaccine. By doing so, 
physicians communicate that parents should not view the HPV vaccine equally as other 
recommended vaccines. While the HPV vaccine may not be the same as other vaccines, 
engaging parents in such a manner provokes anxieties that lead to vaccine refusal. With proper 
provider behavior, these parental anxieties can be assuaged and vaccine behavior can be 
increased.  
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Effective behavioral interventions for patients and providers involve training for 
physicians so as to improve initiation rates and reminder messages for parents to improve 
completion rates. While in-person training sessions for physicians have demonstrated the 
strongest effect on increasing vaccine uptake, such a program would be difficult to implement 
throughout the population. Webinars are a more cost-effective approach though they do not 
provide the same level of engagement that in-person training does. To synthesize the two 
approaches, the AAP has recently released an app called “HPV Vaccine: Same Way, Same 
Day.” The means of delivery for this training app allows physicians to engage with the content, 
is cost effective relative to national in person AFIX training, and provides physicians with the 
freedom to complete the course on their own time. An optimized behavioral intervention for 
providers and patients would implement this app as a requirement for physicians continuing 
education, supplemented with a short reflection to ensure provider engagement, coupled with 
patient reminders to improve chances of vaccine completion.  
While informational interventions did not result in improvements in HPV vaccine uptake 
on an order of magnitude equal to environmental or behavioral approaches, they still are a 
promising way to engage the community on the issues relating to HPV. Efforts in this arena 
should focus on engaging populations through local infrastructure with cultural awareness and 
sensitivity. By operating through trusted, local figures and established institutional frameworks, 
these efforts will improve public knowledge. Additionally, such an approach may help instill a 
sense of trust amongst the community that the information and recommendations delivered to 
them are based on a desire to improve their health outcomes.  
While perhaps a more difficult avenue to institute change, informational interventions 
that target sexual education courses taught to the nation’s youth could result in greater HPV 
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vaccine behavior. Considering that new mothers today were 13 at the time of Gardasil’s release, 
increasing HPV specific knowledge for children today is a means to reduce parental vaccine 
refusal rates in the coming decades.  
 While evaluating immunization efforts at the nationwide level is critical to assess 
progress in achieving vaccination goals, macro-geographic evaluations fail to account for the 
sociodemographic characteristics of smaller communities that affect vaccine behavior. Initiatives 
that are executed on a more local scale are conducted through a less heterogeneous population 
and thus have fewer confounding variables that contribute to barriers to vaccine uptake. By 
examining the sociodemographic characteristics of a small region before making public health 
efforts to increase HPV vaccine uptake, barriers posed by cultural population dynamics can be 
reduced. By identifying communities that act to be representative of certain sociodemographic 
characteristics, a foundation for future interventions can be established.  
Considering all of these evaluations, an optimal intervention requires a synthesis of all 
approaches. By operating through local infrastructures with an awareness of the cultural and 
sociodemographic characteristics that have shaped the community, initiatives can achieve a 
greater rate of success in improving HPV vaccine uptake. Environmental approaches that 
incorporate local awareness into their campaign have a greater chance for improving vaccine 
rates–though school-based programs may continue to face disparate success. Informational 
interventions that tailor their content to local population dynamics should be implemented 
broadly throughout the nation to improve public knowledge and generate patient trust and 
awareness. Behavioral interventions, too, should be maintained by implementing patient 
reminders when possible and requiring recommendation training for pediatricians and family 
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 In many ways, the history of the HPV vaccine in the United States captivates the history 
of American cultural and political ideologies. It captures the ongoing tension between 
governmental authority and individual liberty. It demonstrates the relationship between the 
American consumer, the government, and corporations. It illustrates the healthcare disparities 
experienced by many of the nation’s disadvantaged groups. It portrays the complexities 
associated with navigating topics of gender and sexuality. The HPV vaccine was not inherently 
controversial, it simply held a mirror to the persisting divisions over American ideals. While the 
HPV story shows the consequences of failure, it also shows the hopeful promise of relentless 
perseverance. 
There are many things to be learned through this analysis and now is a particularly 
pressing time to account for the lessons told by the HPV vaccine and its political and cultural 
associations. Vaccine politics and public health efforts are now more relevant than they have 
been in over 100 years. The coronavirus pandemic has reactivated many of the same debates 
around the world that were previously presented by the HPV vaccine. Gardasil proved to be a 
divisive piece of medical technology when it was first released. Inevitably, the new COVID-19 
vaccine will activate similar divisions, though this time they will play out on the global stage. 
While divisions over gender and sexuality may not be as salient an issue for the eventual 
vaccine, many of the anxieties relating to healthcare disparities and governmental authority will 
dominate the conversation.  
The completion of the coronavirus vaccine will subsequently initiate global conflict over 
access to the prophylactic. A primary concern that will need to be addressed is the decision of 
who will get first priority for the vaccine. The supply of vaccines will not be able to meet the 
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global demand and nations will compete amongst each other for a seat at the table. The interstate 
competitions that played out over ventilator access will be magnified on a global scale. Only 
through vaccination will a nation be able to protect its citizens and safely end the economic 
consequences of lockdowns. The citizens of developing nations, where the healthcare 
infrastructures are weak, are the most vulnerable to the pandemic. Despite this demonstrated 
need, developed nations will likely utilize their power on the global stage to provide for their 
citizens first.  
The eventual costs for immunization further raise concerns of vaccine access. 
Pharmaceutical companies have been pouring an exorbitant amount of capital into developing 
the fastest-made vaccine in human history. The large investment by these actors will demand a 
large return. According to Dr. Peter Bach, director at the Center for Health Policy and Outcomes 
at the Memorial Sloan Kettering Cancer Center, “If we depend on the private market to develop 
a vaccine they will demand a very high return for success” (Buchwald, 2020). If this were to 
come to fruition, the coronavirus vaccine would highlight similar concerns as the HPV vaccine 
did over access to an expensive yet medically valuable drug. Poor citizens and poor nations will 
struggle to gain access to the vaccine in such a scenario and will inevitably suffer through the 
consequences.  
In addition to activating similar concerns over access, the coronavirus vaccine will mimic 
Gardasil in its activation of resistance to a perceived coercive government. While it is yet to be 
determined if the coronavirus vaccine will be mandatory, resistance groups have already 
mounted a force against governments. Anti-vaxxers have been extremely vocal at protests in 
recent weeks and express extreme concerns that the eventual vaccine will be forced upon them. 
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Those rising up in resistance assert that they are trying to ensure their individual liberty and that 
this is ultimately about freedom (Bogel-Burroughs, 2020).  
The coronavirus vaccine will be the fastest-developed vaccine in human history. The 
HPV vaccine was fast-tracked for FDA approval and brought before legislations for mandate 
consideration within 2 years of its release. With rapid initiation comes increased skepticism over 
matters of efficacy and safety. Populations across the world will express concern over the 
viability of the developed prophylactic and many will resist participation in global immunization 
efforts. While some governments might aim to overcome this by making vaccination 
compulsory, this will only exacerbate cultural divisions over respect for governmental authority. 
 It is critical to learn from the mistakes made by the HPV vaccine. When divisions were 
heightened by the HPV vaccine, the vaccine failed and so did the public. With coronavirus, the 
stakes are too high to let a similar story play out. The limited access over the vaccine will 
exacerbate global divisions between the haves and have-nots. Despite the limited access, there 
will be significant resistance amongst populations to the vaccine over fears of safety and ideals 
of liberty. To best limit the global damage that such a scenario would provoke, vaccine 
developers must ensure that the vaccine is affordable and governments must do their best to limit 
the perception that their vaccine policies are coercive. Access to the vaccine should be 
determined based on regions that demonstrate the greatest level of need as opposed to a system 
where health and safety is a right only afforded to the wealthy and well connected. While other 
nations may have the healthcare infrastructure to make coronavirus vaccination compulsory, 
such a policy would be damaging in the United States. This would give rise to a large anti-
vaccination movement that could reduce uptake for other standard immunizations.  
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While there are many concerns raised by the eventual release of a coronavirus vaccine, 
there is room for hope. The coronavirus pandemic has resulted in increased concerns over public 
health safety throughout the global population and a greater awareness of the power that vaccines 
possess. While there will be resistance amongst certain sects of the population, the development 
of these vaccines will also likely increase public regard and acceptance for vaccine technologies. 
How this divide in the population is managed will determine the success of the American 
healthcare system for years to come. If the public consensus over vaccines is favorable, vaccine 
uptake may increase and the incidence of vaccine-preventable disease can be reduced. 
Prior to the onset of the pandemic, America was facing a possible paradigm shift in its 
healthcare system. If the coronavirus vaccine rollout is effective and public participation follows, 
America may enter a new age of healthcare prosperity. The effort to eradicate polio gave rise to 
the adoption of Medicaid and Medicare, policies that drastically reduced barriers to healthcare 
access. The coronavirus pandemic has only acted to highlight the inefficiencies and 
vulnerabilities that the existing healthcare structure has, and there is cause to establish a new 
healthcare status quo for Americans where healthcare is a right afforded to all.  
The coronavirus has, will and probably should dominate much of the global dialogue for 
an extended period. While this disease persists, so does HPV. By going through all the discussed 
material, it is clear that HPV is a dangerous disease that is extremely prevalent amongst the 
global population. Infection by the virus is well-established to be associated with the 
development of many life-threatening cancers that affect both men and women. The virus is so 
prevalent that most people in America will contract it at some point in their life if they engage in 
sexual behaviors. While secondary means of prevention like the Pap smear have reduced the 
mortality associated with cervical cancer in the US, preventative screenings do not exist for 
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many HPV-associated cancers. Additionally, the benefits of preventative screenings are not 
afforded to all, as there are numerous individuals in the global and national population that do 
not have adequate access to such procedures. 
 The HPV vaccine is and has been a safe and effective medical technology capable of 
drastically reducing the incidence of HPV infection and the development of HPV-associated 
cancers. Despite the promise the vaccine holds to eliminate an extremely prevalent threat to 
public health, it has faced barriers to its acceptance and incorporation into regular vaccine 
practices. Noting a lack of public knowledge regarding the threat of HPV and its associated 
cancers, Merck engaged in an extensive awareness and marketing campaign for HPV and 
Gardasil. Through these means, they sought to increase public knowledge of certain aspects of 
the disease and vaccine while submerging others. They carried out these actions due to the 
conclusion that by increasing the perceived need of the product while eliminating the cultural 
associations with sexuality, they could maximize profits. These efforts proved to be 
consequential, though, as Merck appeared as a coercive and capital-driven actor despite 
inventing a product that would be a public good. 
 Merck and the population stood to benefit immensely from Gardasil, Merck in terms of 
substantial profits and the public in terms of improved protection against a dangerous infection. 
The extent of these benefits, though, relied upon vast vaccine uptake amongst the population. 
Assuming a reliance upon the existing infrastructure for vaccines, Merck and many public health 
advocates sought to accomplish such a task through legislation for school-aged mandates. Citing 
the successes of a similar vaccine that they produced years earlier, Recombivax, Merck set out to 
lobby for the enactment of vaccine policy. However, these lobbying efforts proved to be 
disastrous when they were revealed to the public. The marketing and lobbying efforts Merck 
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engaged in for Gardasil resulted in increased scrutiny amongst policymakers and the public. 
Policies focused on implementing HPV vaccine mandates ultimately proved to be unsuccessful 
with sparing exceptions. The varieties of skepticism that were directed at the vaccine and its 
associated policies highlighted the cultural divide that existed within America. 
HPV vaccines have failed to be effectively utilized by the American public in the wake of 
the complicated events of the late 2000’s. Institutional barriers to HPV vaccination have been 
reduced and many vaccination initiatives have been conducted as an effort to overcome this 
nationwide reluctance. Of the initiatives implemented, environmental interventions produced the 
largest increase in vaccination and had the greatest reach. However, their success in America is 
limited by a vaccine infrastructure that relies on institutional mandates and clinical 
administration. Acknowledging this American deficiency, an approach that utilizes a 
combination of informational and multi-armed behavioral interventions represents the best 
method for national HPV vaccine improvement. To best implement this line of attack, efforts 
should be made to account for the diversity of the nation. Since the American people are not a 
generalizable group, public health efforts must incorporate the variation in sociodemographic 
characteristics into their initiative calculus. By utilizing a local approach that integrates 
community dynamics, HPV vaccination initiatives can be optimized.  
The HPV vaccine has told a compelling story in America. It captivates the complex 
experiences of a population that struggles to manage the influences of corporations and 
government; the cultural divisions of gender and sexuality; the disparities in access to affordable 
healthcare; and the appropriate balance between individual liberty and governmental authority. 
These complexities have persisted through the years and in some cases have deepened. History 
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doesn’t repeat itself but it does rhyme, and the eventual coronavirus vaccine will ignite these 






















AAP. (n.d.). Grand Rounds / Resident Teaching Sessions. AAP.Org. Retrieved May 9, 2020, 
from http://www.aap.org/en-us/advocacy-and-policy/aap-health-
initiatives/immunizations/HPV-Champion-Toolkit/Pages/Grand-Rounds.aspx 
Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended 
for Children—United States, 1990-1998. (n.d.). Retrieved November 14, 2019, from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/00056803.htm 
Alba, A., Cararach, M., & Rodríguez-Cerdeira, C. (2009). The Human Papillomavirus 
(HPV) in Human Pathology: Description, Pathogenesis, Oncogenic Role, Epidemiology 
and Detection Techniques. https://doi.org/10.2174/1874372200903010090 
Albeck-Ripka, L. (2018, October 3). In Australia, Cervical Cancer Could Soon Be 
Eliminated. The New York Times. 
https://www.nytimes.com/2018/10/03/world/australia/cervical-cancer-hpv-vaccine.html 
Allison, M. A., Hurley, L. P., Markowitz, L., Crane, L. A., Brtnikova, M., Beaty, B. L., 
Snow, M., Cory, J., Stokley, S., Roark, J., & Kempe, A. (2016). Primary Care 
Physicians’ Perspectives About HPV Vaccine. Pediatrics. 
https://doi.org/10.1542/peds.2015-2488 
Aronowitz, R. (2010). Gardasil: A Vaccine against Cancer and a Drug to Reduce Risk. In 
Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple 
Solutions (pp. 21–38). Johns Hopkins University Press. 
Ault, K. A. (2006). Epidemiology and Natural History of Human Papillomavirus Infections 




Bäfverstedt, B. (1967). Condylomata acuminata—Past and present. Acta Dermato-
Venereologica, 47(5), 376–381. 
Bailey, R. (2007, March 20). Why Aren’t More Girls Getting the HPV Vaccine? Detroit 
Free Press. 
Barraza, L., Weidenaar, K., Campos-Outcalt, D., & Yang, Y. T. (2016). Human 
Papillomavirus and Mandatory Immunization Laws. Public Health Reports, 131(5), 
728–731. https://doi.org/10.1177/0033354916663184 
Beavis, A., Krakow, M., Levinson, K., & Rositch, A. F. (2018). Reasons for Lack of HPV 
Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus from Gender and 
Sexuality to Necessity and Safety. Journal of Adolescent Health, 63(5), 652–656. 
https://doi.org/10.1016/j.jadohealth.2018.06.024 
Blake, K. D., Ottenbacher, A. J., Rutten, L. J. F., Grady, M. A., Kobrin, S. C., Jacobson, R. 
M., & Hesse, B. W. (2015). Predictors of Human Papillomavirus Awareness and 
Knowledge in 2013. American Journal of Preventive Medicine, 48(4), 402–410. 
https://doi.org/10.1016/j.amepre.2014.10.024 
Bogel-Burroughs, N. (2020, May 2). Anti-Vaccination Activists Are Growing Force at 
Virus Protests. The New York Times. https://www.nytimes.com/2020/05/02/us/anti-
vaxxers-coronavirus-protests.html 
Brandeis, L. D. & Supreme Court of The United States. (1922) U.S. Reports: Zucht v. King, 
260 U.S. 174. [Periodical] Re. 
Braun, L., & Phoun, L. (2010). HPV Vaccination Campaigns: Masking Uncertainty, Erasing 
Complexity. In Three Shots at Prevention: The HPV Vaccine and the Politics of 
Medicine’s Simple Solutions (pp. 39–60). The Johns Hopkins University Press. 
99 
Brisson, M., Van De Velde, N., & Boily, M. (2009). Economic Evaluation of Human 
Papillomavirus Vaccination in Developed Countries. Public Health Genomics; Basel, 
12(5–6), 343–351. http://dx.doi.org/10.1159/000214924 
Brotherton, J. M. L., Deeks, S. L., Campbell-Lloyd, S., Misrachi, A., Passaris, I., Peterson, 
K., Pitcher, H., Scully, M., Watson, M., & Webby, R. (2008). Interim estimates of 
human papillomavirus vaccination coverage in the school-based program in Australia. 
Communicable Diseases Intelligence Quarterly Report, 32(4), 457–461. 
Brotherton, J. M. L., Murray, S. L., Hall, M. A., Andrewartha, L. K., Banks, C. A., Meijer, 
D., Pitcher, H. C., Scully, M. M., & Molchanoff, L. (2013). Human papillomavirus 
vaccine coverage among female Australian adolescents: Success of the school-based 
approach. The Medical Journal of Australia, 199(9), 614–617. 
https://doi.org/10.5694/mja13.10272 
Brotherton, J. M. L., Zuber, P. L. F., & Bloem, P. J. N. (2016). Primary Prevention of HPV 
through Vaccination: Update on the Current Global Status. Current Obstetrics and 
Gynecology Reports, 5(3), 210–224. https://doi.org/10.1007/s13669-016-0165-z 




Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, 
S., & Castellsagué, X. (2016). Global estimates of human papillomavirus vaccination 
coverage by region and income level: A pooled analysis. The Lancet Global Health, 
4(7), e453–e463. https://doi.org/10.1016/S2214-109X(16)30099-7 
 
100 
Buchwald, E. (n.d.). There’s no guarantee that a coronavirus vaccine will be affordable. 
MarketWatch. Retrieved May 9, 2020, from https://www.marketwatch.com/story/this-
is-what-has-to-happen-for-a-coronavirus-vaccine-to-be-affordable-2020-02-29 
Bui, Q., & Miller, C. C. (2018, August 4). The Age That Women Have Babies: How a Gap 
Divides America. The New York Times. 
https://www.nytimes.com/interactive/2018/08/04/upshot/up-birth-age-gap.html, 
https://www.nytimes.com/interactive/2018/08/04/upshot/up-birth-age-gap.html 
Burd, E. M. (2003). Human Papillomavirus and Cervical Cancer. Clinical Microbiology 
Reviews, 16(1), 1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003 
Bustillos, D. (2016). Political Pitfalls in Policymaking: The Texas HPV Vaccine Policy 
Saga. Narrative Inquiry in Bioethics, 6(1), 6–10. https://doi.org/10.1353/nib.2016.0040 
Caffrey, M. (2018, March 25). Boys Don’t Get HPV Vaccination Because Doctors Don’t 
Recommend It, Study Finds. AJMC. https://www.ajmc.com/conferences/sgo-2018/boys-
dont-get-hpv-vaccination-because-doctors-dont-recommend-it-study-finds 
Cancer Vaccine Bills Stall: Sex, Parenting, Politics: “Perfect Storm” of Controversy Slows 
Acceptance". (2007, May 27). Grand Rapids Press. 
Caskey, R., Andes, S., & Walton, S. M. (2016). HPV vaccine: Less is more. Vaccine, 
34(16), 1863–1864. https://doi.org/10.1016/j.vaccine.2016.02.022 
Caskey, R. N., Macario, E., Johnson, D. C., Hamlish, T., & Alexander, K. A. (2013). A 
School-Located Vaccination Adolescent Pilot Initiative in Chicago: Lessons Learned. 
Journal of the Pediatric Infectious Diseases Society, 2(3), 198–204. 
https://doi.org/10.1093/jpids/pit001 
101 
Casper, M. J., & Carpenter, L. M. (2008). Sex, drugs, and politics: The HPV vaccine for 
cervical cancer. Sociology of Health & Illness, 30(6), 886–899. 
https://doi.org/10.1111/j.1467-9566.2008.01100.x 
Cassidy, B., Braxter, B., Charron-Prochownik, D., & Schlenk, E. A. (2014). A quality 
improvement initiative to increase HPV vaccine rates using an educational and 
reminder strategy with parents of preteen girls. Journal of Pediatric Health Care: 
Official Publication of National Association of Pediatric Nurse Associates & 
Practitioners, 28(2), 155–164. https://doi.org/10.1016/j.pedhc.2013.01.002 
Cates, J. R., Diehl, S. J., Crandell, J. L., & Coyne-Beasley, T. (2014). Intervention effects 
from a social marketing campaign to promote HPV vaccination in preteen boys. 
Vaccine, 32(33), 4171–4178. https://doi.org/10.1016/j.vaccine.2014.05.044 
CDC. (2012, April 20). Human Papillomavirus–Associated Cancers—United States, 2004–
2008. Morbidity and Mortality Weekly Report. 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6115a2.htm?s_cid=mm6115a2_w 
CDC. (2019, March 4). NVSS - Mortality Tables—General Mortality—GMWKI. 
https://www.cdc.gov/nchs/nvss/mortality/gmwki.htm 
CDC. (2020, March 27). How Many Cancers Are Linked with HPV Each Year? | CDC. 
https://www.cdc.gov/cancer/hpv/statistics/cases.htm 
Centers for Disease Control and Prevention (U.S.) (Ed.). (1986). MMWR. Morbidity and 
mortality weekly report, Vol. 35, no. 2, January 17, 1986 (cdc:35444). 35(2). 
https://stacks.cdc.gov/view/cdc/35444 




Cervical Cancer Statistics | CDC. (2019a, July 29). 
https://www.cdc.gov/cancer/cervical/statistics/index.htm 
Cervical Cancer Statistics | CDC. (2019b, July 29). 
https://www.cdc.gov/cancer/cervical/statistics/index.htm 
Chao, C., Preciado, M., Slezak, J., & Xu, L. (2015). A randomized intervention of reminder 
letter for human papillomavirus vaccine series completion. The Journal of Adolescent 
Health: Official Publication of the Society for Adolescent Medicine, 56(1), 85–90. 
https://doi.org/10.1016/j.jadohealth.2014.08.014 
Chapter One (Background). (n.d.). Google Docs. Retrieved May 8, 2020, from 
https://docs.google.com/document/d/1bP2ZrKNAOdFLHm96S8iLNcLNlx0PrOEz80G
P9qRnFBQ/edit?usp=embed_facebook 
Charles, A. S. (2007). The Texas Controversy Over the Cervical Cancer Vaccine (SSRN 
Scholarly Paper ID 1691696). Social Science Research Network. 
https://papers.ssrn.com/abstract=1691696 
Charo, R. A. (2007). Politics, parents, and prophylaxis—Mandating HPV vaccination in the 
United States. The New England Journal of Medicine, 356(19), 1905–1908. 
https://doi.org/10.1056/NEJMp078054 
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., 
Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., Liu, L., Lynch, C. F., 
Wentzensen, N., Jordan, R. C., Altekruse, S., Anderson, W. F., Rosenberg, P. S., & 
Gillison, M. L. (2011). Human papillomavirus and rising oropharyngeal cancer 
incidence in the United States. Journal of Clinical Oncology: Official Journal of the 
103 
American Society of Clinical Oncology, 29(32), 4294–4301. PubMed. 
https://doi.org/10.1200/JCO.2011.36.4596 
Chesler, G., & Kessler, B. (2010). Re-Presenting Choice: Tune in HPV. In Three Shots at 
Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions (pp. 
146–162). The Johns Hopkins University Press. 
Childs, D. (2007, February 27). Political Intrigue in Merck’s HPV Vaccine Push. ABC 
News. https://abcnews.go.com/Health/story?id=2890402&page=1 
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003). Human 
papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. British 
Journal of Cancer, 88(1), 63–73. https://doi.org/10.1038/sj.bjc.6600688 
Colgrove, J. (2006). The Ethics and Politics of Compulsory HPV Vaccination. The New 
England Journal of Medicine; Boston, 355(23), 2389–2391. 
Colgrove, J. (2010). The Coercive Hand, the Beneficent Hand: What the History of 
Compulsory Vaccination Can Tell Us about HPV Vaccine Mandates. In Three Shots at 
Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions (pp. 3–
21). The Johns Hopkins University Press. 
Colgrove, J., Mello, M. M., & Abiola, S. E. (2013). The Politics of HPV Vaccination Policy 
Formation in the United States. Journal of Health Politics, Policy and Law, 38(4), 645–
681. https://doi.org/10.1215/03616878-2208567 
Conrey, R., Valencia, V., Cioletti, A., & Williams-Brown, M. (2020). Regional variation in 
human papillomavirus vaccination uptake and completion among adolescents 13–17 in 
the state of Texas. Vaccine. https://doi.org/10.1016/j.vaccine.2020.03.059 
 
104 
Coughlin, S. S., Richards, T. B., Nasseri, K., Weiss, N. S., Wiggins, C. L., Saraiya, M., 
Stinchcomb, D. G., Vensor, V. M., & Nielson, C. M. (2008). Cervical cancer incidence 
in the United States in the US-Mexico border region, 1998-2003. Cancer, 113(10 
Suppl), 2964–2973. https://doi.org/10.1002/cncr.23748 
cultural cognition project - Cultural Cognition Blog - A case study: The HPV vaccine 
disaster (Science of Science Communication Course, Session 1). (n.d.). Retrieved 
November 25, 2019, from http://www.culturalcognition.net/blog/2013/1/21/a-case-
study-the-hpv-vaccine-disaster-science-of-science-com.html 
Daley, E. M., Vamos, C. A., Thompson, E. L., Zimet, G. D., Rosberger, Z., Merrell, L., & 
Kline, N. S. (2017). The feminization of HPV: How science, politics, economics and 
gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Research, 3, 
142–148. https://doi.org/10.1016/j.pvr.2017.04.004 
Daley, M. F., Kempe, A., Pyrzanowski, J., Vogt, T. M., Dickinson, L. M., Kile, D., Fang, 
H., Rinehart, D. J., & Shlay, J. C. (2014). School-located vaccination of adolescents 
with insurance billing: Cost, reimbursement, and vaccination outcomes. The Journal of 
Adolescent Health: Official Publication of the Society for Adolescent Medicine, 54(3), 
282–288. https://doi.org/10.1016/j.jadohealth.2013.12.011 
Davidson, T. (2017). Vaccines: History, Science, and Issues. ABC-CLIO, LLC. 
http://ebookcentral.proquest.com/lib/utxa/detail.action?docID=4865674 
Davis, E. (2017). What is It to Share Contraceptive Responsibility? Topoi, 36(3), 489–499. 
https://doi.org/10.1007/s11245-015-9342-3 
de Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., & Plummer, M. 
(2012). Global burden of cancers attributable to infections in 2008: A review and 
105 
synthetic analysis. The Lancet. Oncology, 13(6), 607–615. 
https://doi.org/10.1016/S1470-2045(12)70137-7 
de Melo-Martín, I. (2006). The promise of the human papillomavirus vaccine does not 
confer immunity against ethical reflection. The Oncologist, 11(4), 393–396. 
https://doi.org/10.1634/theoncologist.11-4-393 
Dempsey, A. F., & Patel, D. A. (2010). HPV vaccine acceptance, utilization and expected 
impacts in the U.S. Human Vaccines, 6(9), 715–720. 
https://doi.org/10.4161/hv.6.9.12730 
Department of Health and Human Services, & Centers for Disease Control and Prevention. 
(2019, October 22). Vaccine Information Statement | Hepatitis B | VIS | CDC. 
https://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.html 
Dickerson, J. B., Smith, M. L., & Ory, M. G. (2011). Increasing uptake of Gardasil among 
American adolescents: Comparisons with the history of Hepatitis B vaccination. Human 
Vaccines, 7(2), 211–219. https://doi.org/10.4161/hv.7.2.13633 
Dietz, B. (2006, May 23). Vaccine Prevents Cervical Cancer: So, What’s the Down Side? 
The New York Times. 
Dietz, C. A., & Nyberg, C. R. (2011). Genital, Oral, and Anal Human Papillomavirus 
Infection in Men Who Have Sex With Men. The Journal of the American Osteopathic 
Association, 111(3_suppl_2), S19–S25. 
Douglas, A. (1998). Feminization of American Culture. Farrar, Straus and Giroux. 
Down There Health Collective. (2007). HPV Zine. https://myspace.com/downtherehealth 
 
106 
Drutman, L. (2015, April 20). How Corporate Lobbyists Conquered American Democracy. 
The Atlantic. https://www.theatlantic.com/business/archive/2015/04/how-corporate-
lobbyists-conquered-american-democracy/390822/ 
Duffy, J. (1978). School Vaccination: The Precursor to School Medical Inspection. Journal 
of the History of Medicine and Allied Sciences, XXXIII(3), 344–355. 
https://doi.org/10.1093/jhmas/XXXIII.3.344 
Elliott, J., & Ackerman, T. (2007, February 3). Perry vaccine move stirs money, sexual 
concerns. Houston Chronicle. https://www.chron.com/news/health/article/Perry-
vaccine-move-stirs-money-sexual-concerns-1801490.php 
English, A., Shaw, F. E., McCauley, M. M., & Fishbein, D. B. (2008). Legal Basis of 
Consent for Health Care and Vaccination for Adolescents. Pediatrics, 121(Supplement 
1), S85–S87. https://doi.org/10.1542/peds.2007-1115J 
Epstein, S. (2010). The Great Undiscussable: Anal Cancer, HPV, and Gay Men’s Health. In 
Three Shots at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple 
Solutions (pp. 61–90). The Johns Hopkins University Press. 
Fairley, C. K., & Donovan, B. (2010). What can surveillance of genital warts tell us? Sexual 
Health, 7(3), 325–327. https://doi.org/10.1071/SH09145 
Fast Facts | HPV. (n.d.). American Sexual Health Association. Retrieved May 9, 2020, from 
http://www.ashasexualhealth.org/stdsstis/hpv/fast-facts/ 




Fiks, A. G., Grundmeier, R. W., Mayne, S., Song, L., Feemster, K., Karavite, D., Hughes, C. 
C., Massey, J., Keren, R., Bell, L. M., Wasserman, R., & Localio, A. R. (2013). 
Effectiveness of decision support for families, clinicians, or both on HPV vaccine 
receipt. Pediatrics, 131(6), 1114–1124. https://doi.org/10.1542/peds.2012-3122 
Foundation, K. F. (2000). National Survey of Public Knowledge of HPV, the Human 
Papillomavirus. 
Franco, M., Mazzucca, S., Padek, M., & Brownson, R. C. (2019). Going beyond the 
individual: How state-level characteristics relate to HPV vaccine rates in the United 
States. BMC Public Health, 19(1), 246. https://doi.org/10.1186/s12889-019-6566-y 
Freeman HP, & Wingrove BK. (2005). Excess Cervical Cancer Mortality: A Marker for 
Low Access to Health Care in Poor Communities. National Cancer Institute, Center to 
Reduce Cancer Health Disparities, 96. 
Fu, L. Y., Bonhomme, L.-A., Cooper, S. C., Joseph, J. G., & Zimet, G. D. (2014). 
Educational interventions to increase HPV vaccination acceptance: A systematic 
review. Vaccine, 32(17), 1901–1920. https://doi.org/10.1016/j.vaccine.2014.01.091 
Garber, J. (2017, November 14). HPV protection or cancer vaccine? Putting Gardasil in 
context. Lown Institute. https://lowninstitute.org/news/hpv-vaccine-cancer-vaccine-
putting-gardasil-context/ 
Garnock-Jones, K. P., & Giuliano, A. R. (2011). Quadrivalent human papillomavirus (HPV) 
types 6, 11, 16, 18 vaccine: For the prevention of genital warts in males. Drugs, 71(5), 
591–602. https://doi.org/10.2165/11205980-000000000-00000 
Gerend, M. A., & Shepherd, J. E. (2012). Predicting human papillomavirus vaccine uptake 
in young adult women: Comparing the health belief model and theory of planned 
 
108 
behavior. Annals of Behavioral Medicine: A Publication of the Society of Behavioral 
Medicine, 44(2), 171–180. https://doi.org/10.1007/s12160-012-9366-5 
Gibbs, N. (2006, June 21). Defusing the War Over the “Promiscuity” Vaccine. Time. 
http://content.time.com/time/nation/article/0,8599,1206813,00.html 
Gilkey, M. B., Dayton, A. M., Moss, J. L., Sparks, A. C., Grimshaw, A. H., Bowling, J. M., 
& Brewer, N. T. (2014). Increasing provision of adolescent vaccines in primary care: A 
randomized controlled trial. Pediatrics, 134(2), e346-353. 
https://doi.org/10.1542/peds.2013-4257 
Gilkey, M. B., Malo, T. L., & Brewer, N. T. (2016). Quality of Physician Communication 
about HPV Vaccine – Reply. Cancer Epidemiology, Biomarkers & Prevention : A 
Publication of the American Association for Cancer Research, Cosponsored by the 
American Society of Preventive Oncology, 25(5), 868. https://doi.org/10.1158/1055-
9965.EPI-16-0113 
Godlee, F., Smith, J., & Marcovitch, H. (2011). Wakefield’s article linking MMR vaccine 
and autism was fraudulent. BMJ. https://doi.org/10.1136/bmj.c7452 
Gold, R., Naleway, A. L., Jenkins, L. L., Riedlinger, K. K., Kurosky, S. K., Nystrom, R. J., 
& Kurilo, M. B. (2011). Completion and timing of the three-dose human papillomavirus 
vaccine series among adolescents attending school-based health centers in Oregon. 
Preventive Medicine, 52(6), 456–458. https://doi.org/10.1016/j.ypmed.2011.04.010 
Gottleib, S. (2018). Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer. Rutgers 
University Press. 
Grady, D. (2007, March 6). A Vital Discussion, Clouded. The New York Times. 
https://www.nytimes.com/2007/03/06/health/06seco.html 
109 
Harper, D. M., & DeMars, L. R. (2017). HPV vaccines – A review of the first decade. 
Gynecologic Oncology, 146(1), 196–204. https://doi.org/10.1016/j.ygyno.2017.04.004 
Healthcare-Professional-Key-Messages-508.pdf. (n.d.). Retrieved May 7, 2020, from 
https://www.cdc.gov/vaccines/events/niam/downloads/Healthcare-Professional-Key-
Messages-508.pdf 
Hepatitis B Foundation. (2020). What is Hepatitis B? https://www.hepb.org/what-is-
hepatitis-b/what-is-hepb/ 
Hill, H. A. (2018). Vaccination Coverage Among Children Aged 19–35 Months—United 
States, 2017. MMWR. Morbidity and Mortality Weekly Report, 67. 
https://doi.org/10.15585/mmwr.mm6740a4 
HINTS_Brief_26.pdf. (n.d.). Retrieved April 29, 2020, from 
https://hints.cancer.gov/docs/Briefs/HINTS_Brief_26.pdf 
Hoffman, J. (2019, September 23). How Anti-Vaccine Sentiment Took Hold in the United 
States. The New York Times. https://www.nytimes.com/2019/09/23/health/anti-
vaccination-movement-us.html 
Hopfer, S. (2012). Effects of a narrative HPV vaccination intervention aimed at reaching 
college women: A randomized controlled trial. Prevention Science: The Official 
Journal of the Society for Prevention Research, 13(2), 173–182. 
https://doi.org/10.1007/s11121-011-0254-1 





Human Papillomavirus (HPV) Vaccines to Prevent Cancer • iBiology. (n.d.). IBiology. 
Retrieved May 8, 2020, from https://www.ibiology.org/human-disease/hpv/ 
Hussain, A., Ali, S., Ahmed, M., & Hussain, S. (2018). The Anti-vaccination Movement: A 
Regression in Modern Medicine. Cureus, 10(7). https://doi.org/10.7759/cureus.2919 
Jenco, M. (2019). Study: Physicians make stronger HPV vaccination recommendations for 
older children. Infectious Diseases, 2. 
Johnson. (1964, September 7). Political Ad: “Daisy Ad.” 
https://archives.nbclearn.com/portal/site/k-12/browse/?cuecard=2362 
Kempe, A., Barrow, J., Stokley, S., Saville, A., Glazner, J. E., Suh, C., Federico, S., 
Abrams, L., Seewald, L., Beaty, B., Daley, M. F., & Dickinson, L. M. (2012). 
Effectiveness and cost of immunization recall at school-based health centers. 
Pediatrics, 129(6), e1446-1452. https://doi.org/10.1542/peds.2011-2921 
Kempe, A., O’Leary, S. T., Markowitz, L. E., Crane, L. A., Hurley, L. P., Brtnikova, M., 
Beaty, B. L., Meites, E., Stokley, S., & Lindley, M. C. (2019). HPV Vaccine Delivery 
Practices by Primary Care Physicians. Pediatrics, 144(4). 
https://doi.org/10.1542/peds.2019-1475 
Kharbanda, E. O., Stockwell, M. S., Fox, H. W., Andres, R., Lara, M., & Rickert, V. I. 
(2011). Text message reminders to promote human papillomavirus vaccination. 
Vaccine, 29(14), 2537–2541. https://doi.org/10.1016/j.vaccine.2011.01.065 
Kim, J. J. (2010). Targeted human papillomavirus vaccination of men who have sex with 
men in the USA: A cost-effectiveness modelling analysis. The Lancet. Infectious 
Diseases, 10(12), 845–852. https://doi.org/10.1016/S1473-3099(10)70219-X 
111 
King, M. (2004, September 10). Toomey’s out, Delisi’s in. 
https://www.austinchronicle.com/news/2004-09-10/228246/ 
Korioth, T. (2018). Boost HPV vaccination rates with these 3 tools. AAP News. 
https://www.aappublications.org/news/2018/06/06/fyihpv060618 
Kreuter, M. W., & Wray, R. J. (2003). Tailored and Targeted Health Communication: 
Strategies for Enhancing Information Relevance. American Journal of Health Behavior, 
27(1), S227–S232. 
KXAN.com. (2007, February 20). Public Hearing on HPV Vaccine Went until Midnight. 
https://www.kxan.com/Global/story.asp?S=6107668&nav=menu73_2_6 
Lakoff, A. (2015). Vaccine Politics and the Management of Public Reason. Public Culture, 
27(3 (77)), 419–425. https://doi.org/10.1215/08992363-2896159 
Lam, B. (2015, February 10). Vaccines Are Profitable, So What? The Atlantic. 
https://www.theatlantic.com/business/archive/2015/02/vaccines-are-profitable-so-
what/385214/ 
Lawmakers Rethinking How to Cure Cancer. (2007, June 9). Grand Rapid Press. 
Lee, L., & Garland, S. M. (2017). Human papillomavirus vaccination: The population 
impact. F1000Research, 6. https://doi.org/10.12688/f1000research.10691.1 
Lehtinen, M., Pavane, J., Wheeler, C. M., Jaskaran, U., Garland, S. M., Castellsagué, X., 
Skinner, S. R., Pater, D., Nafud, P., Salmeron, J., Chow, S.-N., Kitchener, H., Teixeira, 
J. C., Hedrick, J., Limon, G., Swarovski, A., Romanowski, B., Aoki, F. Y., Schwarz, T. 
F., … Dubbin, G. (2012). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine 
against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis 
 
112 
of the randomized, double-blind PATRICIA trial. The Lancet Oncology, 13(1), 89–99. 
https://doi.org/10.1016/S1470-2045(11)70286-8 
Levine, S. (2007, March 2). Parents Question HPV Vaccine, Push to Mandate Shots Rapidly 
Creates Backlash. The Washington Post. 
Livingston, J., Walloon, K., & Cooper, B. (2010). Vaccination as Governance: HPV 
Skepticism in the United States and Africa, and the North-South Divide. In Three Shots 
at Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions (pp. 
231–253). The Johns Hopkins University Press. 
Lo, B. (2006). HPV vaccine and adolescents’ sexual activity. BMJ: British Medical Journal, 
332(7550), 1106–1107. 
Lowy, D. R., & Schiller, J. T. (2006). Prophylactic human papillomavirus vaccines. The 
Journal of Clinical Investigation, 116(5), 1167–1173. https://doi.org/10.1172/JCI28607 
Macartney, K. K., Chiu, C., Georgousakis, M., & Brotherton, J. M. L. (2013). Safety of 
human papillomavirus vaccines: A review. Drug Safety, 36(6), 393–412. 
https://doi.org/10.1007/s40264-013-0039-5 
Mamo, L., & Epstein, S. (2017). The new sexual politics of cancer: Oncoviruses, disease 
prevention, and sexual health promotion. BioSocieties; London, 12(3), 367–391. 
http://dx.doi.org.ezproxy.lib.utexas.edu/10.1057/biosoc.2016.10 
Manhart, L. E., & Koutsky, L. A. (2002). Do Condoms Prevent Genital HPV Infection, 
External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis. Sexually Transmitted 
Diseases, 29(11), 725. 
113 
McGraw, S. L., & Ferrante, J. M. (2014). Update on prevention and screening of cervical 
cancer. World Journal of Clinical Oncology, 5(4), 744–752. 
https://doi.org/10.5306/wjco.v5.i4.744 
McQuillan, G., & Unger, E. R. (2017). Prevalence of HPV in Adults Aged 18–69: United 
States, 2011–2014. 280, 8. 
Measles explained: What’s behind the recent outbreaks? (n.d.). Retrieved May 8, 2020, 
from https://www.unicef.org/stories/measles-explained-whats-behind-recent-outbreaks 
Mello, M. M., Abiola, S., & Colgrove, J. (2012). Pharmaceutical Companies’ Role in State 
Vaccination Policymaking: The Case of Human Papillomavirus Vaccination. American 
Journal of Public Health; Washington, 102(5), 893–898. 
Merck. (2005). DDB - HPV.com—Tell Someone. 
https://www.youtube.com/watch?v=4yV7SpHOcrw 
Merck. (2006). One Less Commercial for Gardasil. 
https://www.youtube.com/watch?v=hJ8x3KR75fA 
Mesher, D., Panwar, K., Thomas, S. L., Beddows, S., & Soldan, K. (2016). Continuing 
reductions in HPV 16/18 in a population with high coverage of bivalent HPV 
vaccination in England: An ongoing cross-sectional study. BMJ Open, 6(2), e009915. 
https://doi.org/10.1136/bmjopen-2015-009915 
Millikan, A. (2006, October 30). HPV vaccine goes unused. The Michigan Daily. 
https://www.michigandaily.com/content/hpv-vaccine-goes-unused 




Molokwu, J., Dwivedi, A., Mallawaarachchi, I., Hernandez, A., & Shokar, N. (2019). 
Tiempo de Vacunarte (time to get vaccinated): Outcomes of an intervention to improve 
HPV vaccination rates in a predominantly Hispanic community. Preventive Medicine, 
121, 115–120. https://doi.org/10.1016/j.ypmed.2019.02.004 
Moore, G. R., Crosby, R. A., Young, A., & Charnigo, R. (2010). Low rates of free human 
papillomavirus vaccine uptake among young women. Sexual Health, 7(3), 287–290. 
PubMed. https://doi.org/10.1071/sh09136 
More Re: Merck’s “Help Pay for Vioxx” Mandatory Vaccine Campaign. (2007, February 
8). Alliance for Human Research Protection. https://ahrp.org/more-re-mercks-help-pay-
for-vioxx-mandatory-vaccine-campaign/ 
Most American adults do not know that HPV causes oral, anal, and penile cancers. (n.d.). 
EurekAlert! Retrieved April 29, 2020, from 
https://www.eurekalert.org/pub_releases/2019-09/uoth-maa091219.php 
National Conference of State Legislatures. (2018, June 12). HPV Vaccine: State Legislation 
and Statutes. https://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-
statutes.aspx 
Navarrete, J. P., Padilla, M. E., Castro, L. P., & Rivera, J. O. (2014). Development of a 
community pharmacy human papillomavirus vaccine program for underinsured 
university students along the United States/Mexico border. Journal of the American 
Pharmacists Association: JAPhA, 54(6), 642–647. 
https://doi.org/10.1331/JAPhA.2014.13222 
115 
NCI Dictionary of Cancer Terms (nciglobal,ncienterprise). (2011, February 2). 
[NciAppModulePage]. National Cancer Institute. 
https://www.cancer.gov/publications/dictionaries/cancer-terms 
NHPC Press Release: Schools Teaching Prevention | 2015 | Newsroom | NCHHSTP | CDC. 
(2019, May 21). https://www.cdc.gov/nchhstp/newsroom/2015/nhpc-press-release-
schools-teaching-prevention.html 
NIH. (1996). The National Institutes of Health (NIH) Consensus Development Program: 
Cervical Cancer. https://consensus.nih.gov/1996/1996cervicalcancer102html.htm 
NormileMay. 11, D., 2018, & Pm, 12:25. (2018, May 11). Journal retracts paper claiming 
neurological damage from HPV vaccine. Science | AAAS. https://www-sciencemag-
org.ezproxy.lib.utexas.edu/news/2018/05/journal-retracts-paper-claiming-neurological-
damage-hpv-vaccine 
Office of Disease Prevention and Health Promotion. (2010). Immunization and Infectious 
Diseases | Healthy People 2020. https://www.healthypeople.gov/2020/topics-
objectives/topic/immunization-and-infectious-diseases/objectives 
Opel, D. J., Mangione-Smith, R., Robinson, J. D., Heritage, J., DeVere, V., Salas, H. S., 
Zhou, C., & Taylor, J. A. (2015). The Influence of Provider Communication Behaviors 
on Parental Vaccine Acceptance and Visit Experience. American Journal of Public 
Health, 105(10), 1998–2004. https://doi.org/10.2105/AJPH.2014.302425 
Osazuwa-Peters, N., Adjei Boakye, E., Mohammed, K. A., Tobo, B. B., Geneus, C. J., & 
Schootman, M. (2017). Not just a woman’s business! Understanding men and women’s 
knowledge of HPV, the HPV vaccine, and HPV-associated cancers. Preventive 
Medicine, 99, 299–304. https://doi.org/10.1016/j.ypmed.2017.03.014 
 
116 
Oudshoorn, N. (Ed.). (2003). Designing Technology and Masculinity: Challenging the 
Invisibility of Male Reproductive Bodies in Scientific Medicine. In The Male Pill: A 
Biography of a Technology in the Making (p. 0). Duke University Press. 
https://doi.org/10.1215/9780822385226-001 
Pap Smear | Additional Resources | Imaginis—The Women’s Health & Wellness Resource 
Network. (n.d.). Retrieved May 8, 2020, from https://www.imaginis.com/womens-
health/pap-smear-2 
Pelling: Contagion: Historical and Cultural Studies—Google Scholar. (n.d.). Retrieved 
May 15, 2019, from 
https://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=A.+
Bashford&author=C.+Hooker&title=Contagion%3A+Historical+and+Cultural+Studies 
Perkins, R. B., Zisblatt, L., Legler, A., Trucks, E., Hanchate, A., & Gorin, S. S. (2015). 
Effectiveness of a provider-focused intervention to improve HPV vaccination rates in 
boys and girls. Vaccine, 33(9), 1223–1229. 
https://doi.org/10.1016/j.vaccine.2014.11.021 
Perry, R. (2007). Statement of Gov. Rick Perry on HPV Vaccine Executive Order. 
Polzer, J. C., & Knabe, S. M. (2012). From desire to disease: Human papillomavirus (HPV) 
and the medicalization of nascent female sexuality. Journal of Sex Research, 49(4), 
344–352. https://doi.org/10.1080/00224499.2011.644598 
Prescott, H. (2010). Safeguarding Girls: Morality, Risk, and Activism. In Three Shots at 
Prevention: The HPV Vaccine and the Politics of Medicine’s Simple Solutions (pp. 
103–120). The Johns Hopkins University Press. 
Radosevich, J. (2012). HPV and Cancer. Springer. 
117 
Rahman, M., McGrath, C. J., & Berenson, A. B. (2014). Geographic variation in human 
papillomavirus vaccination uptake among 13-17 year old adolescent girls in the United 
States. Vaccine, 32(21), 2394–2398. https://doi.org/10.1016/j.vaccine.2014.02.097 
Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L. D., Singleton, J. A., Curtis, C. 
R., MacNeil, J., Markowitz, L. E., & Stokley, S. (2015). National, Regional, State, and 
Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years—
United States, 2014. MMWR. Morbidity and Mortality Weekly Report, 64(29), 784–792. 
PubMed. https://doi.org/10.15585/mmwr.mm6429a3 
Redmond, M. A. (2011). A Critical Discourse Analysis of the Marketing of Merck & Co.’s 
Human Papillomavirus Vaccine Gardasil®. 94. 
Rickert, V. I., Auslander, B. A., Cox, D. S., Rosenthal, S. L., Rupp, R. E., & Zimet, G. D. 
(2015). School-based HPV immunization of young adolescents: Effects of two brief 
health interventions. Human Vaccines & Immunotherapeutics, 11(2), 315–321. 
https://doi.org/10.1080/21645515.2014.1004022 
Rothman, S. M., & Rothman, D. J. (2009). Marketing HPV vaccine: Implications for 
adolescent health and medical professionalism. JAMA, 302(7), 781–786. 
https://doi.org/10.1001/jama.2009.1179 
Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N., & Weinstein, M. C. (1996). The role 
of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in 
Health and Medicine. JAMA, 276(14), 1172–1177. 
Safaeian, M., Sampson, J. N., Pan, Y., Porras, C., Kemp, T. J., Herrero, R., Quint, W., van 
Doorn, L. J., Schussler, J., Lowy, D. R., Schiller, J., Schiffman, M. T., Rodriguez, A. 
C., Gail, M. H., Hildesheim, A., Gonzalez, P., Pinto, L. A., Kreimer, A. R., & Costa 
 
118 
Rica HPV Vaccine Trial (CVT) Group. (2018). Durability of Protection Afforded by 
Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Journal of the National 
Cancer Institute, 110(2). https://doi.org/10.1093/jnci/djx158 
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007). 
Human papillomavirus and cervical cancer. Lancet, 370, 18. 
Schuchat, A. (2015). HPV “Coverage.” New England Journal of Medicine, 372(8), 775–
776. https://doi.org/10.1056/NEJMe1415742 
Siers-Poisson, J. (2007). Research, Develop, and Sell, Sell, Sell: Part Two in a series on the 
Politics and PR of Cervical Cancer. http://www.prwatch.org/news/207/06/6208 
Siers-Poisson, Judith. (2007, July 10). Women in Government, Merck’s Trojan Horse: Part 
Three in a Series on the Politics and PR of Cervical Cancer | Center for Media and 
Democracy. 
https://web.archive.org/web/20081201131753/http://www.prwatch.org/node/6232/ 
Silverman, E. (2005, April 12). “Parents Balk at Idea of STD Vaccine for Kids.” Muskegon 
(MI) Chronicle. 
Spinner, C., Ding, L., Bernstein, D. I., Brown, D. R., Franco, E. L., Covert, C., & Kahn, J. 
A. (2019). Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young 
Women. Pediatrics, 143(2). https://doi.org/10.1542/peds.2018-1902 
STD Facts—Human papillomavirus (HPV). (2019, September 12). 
https://www.cdc.gov/std/hpv/stdfact-hpv.htm 
Street, W. (1930). Cancer Facts & Figures 2019. 76. 
119 
Stubbs, B. W., Panizza, C. A., Moss, J. L., Reiter, P. L., Whitesell, D. H., & Brewer, N. T. 
(2014). Evaluation of an intervention providing HPV vaccine in schools. American 
Journal of Health Behavior, 38(1), 92–102. https://doi.org/10.5993/AJHB.38.1.10 
Suk, R., Montrealer, J. R., Nimule, G. S., Nitra, A. G., Scheler, K. M., Sona wane, K., & 
Deshmukh, A. A. (2019). Public Knowledge of Human Papillomavirus and Receipt of 
Vaccination Recommendations. JAMA Pediatrics. 
https://doi.org/10.1001/jamapediatrics.2019.3105 
Suryadevara, M., Bonville, C. A., Cibola, D. A., Tomahawks, J. B., & Suryadevara, A. C. 
(2019). Associations between population-based voting trends during the 2016 US 
presidential election and adolescent vaccination rates. Vaccine, 37(9), 1160–1167. 
https://doi.org/10.1016/j.vaccine.2019.01.036 
Suryadevara, M., Bonville, C. A., Ferraioli, F., & Tomahawks, J. B. (2013). Community-
centered education improves vaccination rates in children from low-income households. 
Pediatrics, 132(2), 319–325. https://doi.org/10.1542/peds.2012-3927 
Talking with Parents about Vaccines for Infants | CDC. (2019, April 1). 
https://www.cdc.gov/vaccines/hcp/conversations/talking-with-parents.html 
The Texas House of Representatives. (2007, April 5). The official Website for the Texas 
House of Representatives.  The Texas House of Representatives. Retrieved on April 5 
2007 from http: //Www.legis.tx.us/tldocs/80R/billtext/doc/HB00215I.doc. 
http://www.legis.tx.us/tldocs/80R/billtext/doc/HB00215I.doc 
Tomljenovic, L., & Shaw, C. A. (2012). Too fast or not too fast: The FDA’s approval of 
Merck’s HPV vaccine Gardasil. The Journal of Law, Medicine & Ethics: A Journal of 
 
120 
the American Society of Law, Medicine & Ethics, 40(3), 673–681. 
https://doi.org/10.1111/j.1748-720X.2012.00698.x 
Tribune, T. T. (2007, February 12). Need to Hide Something Big? The Texas Tribune. 
https://www.texastribune.org/texas-weekly/vol-23/no-32/need-to-hide-something-big/ 
U.S. Department of Health and Human Services (DHHS), & National Center for 
Immunization and Respiratory Diseases (NCIRD). (2020). The 2018 National 
Immunization Survey—Teen. Centers for Disease Control and Prevention. 
Vaccination Coverage Rates: Department of Health. (n.d.). Retrieved May 9, 2020, from 
https://health.ri.gov/data/vaccination/ 
Vaccine Faces Scrutiny: Effectiveness against HPV, Cervical Cancer Questioned. (2007, 
May 10). Grand Rapid Press. 
Vaccines: Vac-Gen/Side Effects. (2020, April 2). https://www.cdc.gov/vaccines/vac-
gen/side-effects.htm 
Wailoo, K., Livingston, J., Epstein, S., & Aronowitz, R. (2010). Three Shots at Prevention: 
The HPV Vaccine and the Politics of Medicine’s Simple Solutions. JHU Press. 
Wakefield, A., Murch, S., Anthony, A., Linnell, J., Casson, D., Malik, M., Berelowitz, M., 
Dhillon, A., Thomson, M., Harvey, P., Valentine, A., Davies, S., & Walker-Smith, J. 
(1998). RETRACTED: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and 
pervasive developmental disorder in children. The Lancet, 351(9103), 637–641. 
https://doi.org/10.1016/S0140-6736(97)11096-0 
Walker, T. Y. (2017). National, Regional, State, and Selected Local Area Vaccination 
Coverage Among Adolescents Aged 13–17 Years—United States, 2016. MMWR. 
Morbidity and Mortality Weekly Report, 66. https://doi.org/10.15585/mmwr.mm6633a2 
121 
Walling, E. B., Benzoni, N., Dornfeld, J., Bhandari, R., Sisk, B. A., Garbutt, J., & Colditz, 
G. (2016). Interventions to Improve HPV Vaccine Uptake: A Systematic Review. 
PEDIATRICS, 138(1), e20153863–e20153863. https://doi.org/10.1542/peds.2015-3863 
Walters, E. (2019, August 12). Texas almost mandated an HPV vaccine before politics got 
in the way. Now, the state has one of the country’s highest rates of cervical cancer. The 
Texas Tribune. https://www.texastribune.org/2019/08/12/texas-low-rate-hpv-
vaccination-keeping-cervical-cancer-rates-high/ 
Westbrook, L., & Fourie, I. (2015). A feminist information engagement framework for 
gynecological cancer patients: The case of cervical cancer. Journal of Documentation, 
71(4), 752–774. https://doi.org/10.1108/JD-09-2014-0124 
WHO | Safety update of HPV vaccines. (n.d.). WHO; World Health Organization. Retrieved 
May 8, 2020, from 
http://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/ 
Williams, W. (2013). Noninfluenza Vaccination Coverage Among Adults—United States, 
2011. MMWR. Morbidity and Mortality Weekly Report, 62(04), 66–72. 
Winer, R. L., Feng, Q., Hughes, J. P., O’Reilly, S., Kiviat, N. B., & Koutsky, L. A. (2008). 
Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex 
Partner. The Journal of Infectious Diseases, 197(2), 279–282. 
https://doi.org/10.1086/524875 
Women in Government. (2011, November). A Roadmap for Success: The State of Cervical 
Cancer Prevention in America 2010. https://www.womeningovernment.org/ 
Women in Government Report. (2008). The ‘State’ of Cervical Cancer Prevention in 
America—2008: Turning Challenges into Opportunities. 
 
122 
Zimm, A., & Bloom, J. (2006, May 26). Merck Promotes Cervical Cancer Shot by 























James Hawley was born in Minneapolis, Minnesota on January 7, 1997 and raised there 
throughout his youth. He enrolled in the Plan II Honors program at the University of Texas at 
Austin in 2015 and studied psychology and health sciences. In college, he conducted cancer 
research with doctors at The University of Texas MD Anderson Cancer Center and biked to 
Alaska as a part of the 2018 Texas 4,000 for Cancer team. He graduated in 2019 and is currently 
working as a medical scribe and contact tracer. He is applying to medical school this spring. 
